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ABSTRACT OF THE DISSERTATION
Chitosan Decontamination with Non-Thermal Nitrogen Plasma
to Enable Internal Use
by
Andrew R. Crofton
Doctor of Philosophy, Graduate Program in Anatomy
Loma Linda University, March 2016
Dr. Wolff M. Kirsch, Chairperson

Chitosan (CS) is a ubiquitous biopolymer and is recognized as a
promising biomedical material. Potential medical applications for chitosan are
extensive and many have shown impressive results. However, chitosan is
clinically only used as a topical hemostatic agent due to an inability to sterilize
and depyrogenate chitosan without negatively altering its physical and biological
properties with conventional techniques. We hypothesized that non-thermal
nitrogen plasma (NtNP) would sterilize and depyrogenate chitosan while
preserving its biological properties. Since plasma is a surface treatment, we
micronized chitosan using cryo-ball and cryo-jet milling to increase its surface to
volume ratio. Cryo-jet milling produced the smallest mean particle size (16.05
μm) and reduced molecular weight 36.5% (MW) and degree of deacetylation
(DD) 9.6%. NtNP treatment of the resultant chitosan powder produced a sterile
chitosan with endotoxin levels <2.50 EU/g, but further reduced MW 40% and DD
6.3%. Nitrogen content and bioadhesivity were unaltered. We tested biologic
functionality in a murine orthotopic bladder cancer model in which a previous
study showed chitosan dramatically enhanced anti-tumor properties of

xv

interleukin-12 (IL-12). We found that bladder tumors regressed – and mice
survived to 90 days – in 88% (n=16) and 92% (n=12) of C57Bl/6 mice treated
with unsterile chitosan+IL-12 and plasma-sterilized chitosan+IL-12, respectively,
but only 8% (n=12) and 0% (n=3) of mice treated with saline and CS-alone,
respectively. All plasma-sterilized chitosan+IL-12 (n=11) and 92% of unsterile
chitosan+IL-12 (n=13) treated mice rejected tumors upon re-challenge. These
results are equivalent to the previously published chitosan+IL-12 study
suggesting NtNP sterilization preserved the biological properties of chitosan. A
rat model showed that hemostatic chitosan pads sterilized with electron beam
irradiation and NtNP stopped femoral artery and artery/vein bleeding better than
pads treated with either treatment alone and equivalent to unsterilized pads. A
porcine kidney bleeding model showed that NtNP-sterilized pads had superior
hemostatic properties compared to e-beam sterilized pads. No complications
associated with implanting the pads were observed 14-weeks post-operatively.
Histologic examination demonstrated tissue and inflammatory reactions
characteristic of foreign body implants. Knowledge gained in these studies will
allow clinical testing of parenteral applications of chitosan, including immediate
trials of chitosan+IL-12 in bladder cancer patients.
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CHAPTER ONE
INTRODUCTION
Background
Alzheimer’s Disease
Dr. Kirsch’s laboratory has been studying Alzheimer’s disease (AD) since
the early 2000s after 2 amino acids his laboratory discovered in the early 1980s,
aminomalonic acid and beta carboxyaspartic acid, were subsequently linked to
iron homeostasis and aging. (Christy, 1981; Christy, 1982; Van Buskirk, 1984;
Wheelan, 1989-A; Wheelan, 1989-B) The link was based on the finding that iron
will bind to iron regulatory protein 2 (IRP2) under conditions of sufficient iron
levels in the cell, which catalyzes an oxidative modification of IRP2 that converts
a cysteine residue to aminomalonic acid. (Kang, 2003) This modification triggers
proteasomal degradation of IRP2. This discovery led Dr. Kirsch to apply for an
R01 grant from the NIH, which was funded, to study how IRP2 might be involved
in perturbations in iron hemostasis that had been observed in AD.
Dr. Kirsch’s study of IRP2 led to the discovery that polymorphisms in the
gene encoding IRP2 (IREB2) are significantly associated with AD, but expression
levels and localization of the IRP2 protein are not altered in the hippocampus of
AD patients. (Coon, 2006; Magaki, 2007) However, loosely bound iron was
decreased in the hippocampus of AD patients and increased in brains of
transgenic IRP2 knockout (-/-) mice. (Magaki, 2007-A; Magaki, 2007-B) This
finding of decreased iron in the AD hippocampus directly contradicted many
other studies in the literature. Since the human studies from Dr. Kirsch’s
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laboratory were performed on human brains categorized on both AD and
presence and severity of cerebral amyloid angiopathy (CAA), a common vascular
co-morbidity with AD not commonly examined in AD studies, it was hypothesized
that iron was increased in CAA patients due to microhemorrhages and this
skewed findings of previous studies quantitating iron in post-mortem AD brains.
Initial evidence supporting this hypothesis came in the form of susceptibilityweighted imaging (SWI), a magnetic resonance imaging (MRI) sequence
exceptionally sensitive for detecting iron, that showed greater numbers of
microbleeds in the brains of CAA than AD patients. (Schrag, 2010; Ayaz, 2010) A
meta-analysis by Schrag et al subsequently demonstrated that a series of
publications from one laboratory had reported significantly higher iron levels in
AD brain than other studies. (Schrag, 2011) When those studies were removed
from the analysis, there was no longer a statistically significant difference in iron
levels in AD brains compared to age-matched controls. However, copper (Cu)
remained significantly decreased (p=0.0003).

Copper
In the course of the iron studies, a link had been discovered between IRP2
and Cu in the IRP2 knockout mice mentioned above. Specifically, it was
discovered that IRP2 knockout mice had significantly lower Cu levels in multiple
brain regions, including the hippocampus, at 6 weeks of age compared to wildtype mice. (Mueller, 2009) This decrease in hippocampal Cu was correlated with
increased expression of amyloid precursor protein (APP), a known Cu-binding
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protein thereby suggesting that a possible mechanism for this observed change
in Cu might be a change in APP due to IRP2 dyshomeostasis.
When I joined Dr. Kirsch’s laboratory, studies measuring Cu and iron
concentrations in serum from AD patients and controls were ongoing. In these
studies, we found that the ratio of Cu to non-heme iron predicted which patients
with mild cognitive impairment (MCI) would progress to AD over a 5-year period.
(Mueller, 2012) We also correlated these findings with longitudinal studies of
serum protein markers, which showed changes in the complement system.
(Zabel, 2012) Subsequent studies on complement found a switch in the
mechanism of amyloid clearance from the brains of CAA patients compared to
AD and control that involved complement proteins. (Zabel, 2013) We believe this
mechanism might explain the vascular fragility associated with CAA. As such,
studies aimed at developing a targeted therapy for abnormal complement
activation on cerebral microvessels are currently underway in Dr. Kirsch’s
laboratory.
To strengthen our initial studies on iron and Cu in the blood of AD
patients, we performed a meta-analysis to examine changes in oxidative stress in
the blood of AD and MCI patients. In this study, we found that markers of lipid
peroxidation, which can occur with abnormalities in transition metal homeostasis,
are elevated in the blood in AD and MCI patients. Furthermore, we found
evidence of Cu metabolism abnormalities and reduced total antioxidant capacity.
(Schrag, 2013) Thus, there was strong evidence to continue studying changes in
Cu in AD and CAA brains.
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Our initial studies found that Cu was decreased in post-mortem brains of
both AD and AD+CAA patients compared to age-matched controls. Cu was
significantly deposited on the vasculature in CAA as well. (Schrag, 2011) Thus, it
appeared that Cu was perturbed in both AD and CAA, though the observed
changes were different for the two diseases, suggesting different
pathophysiological mechanisms.
Studies on Cu were expanded to begin understanding the extent of Cu
dyshomeostasis in AD. Those studies were the focus of my early work in Dr.
Kirsch’s laboratory. The primary results showed that Cu was significantly
decreased in synaptic vesicles of AD brains (Figure 1), but a fluorescent probe
for monovalent Cu showed a staining pattern that indicated an increase in
intracellular Cu (Figure 2).

4

Figure 1. Copper concentration in synaptic vesicles. Synaptic vesicles were
isolated via ultra-centrifugation from age-matched control, AD-only, and AD+CAA
temporal lobe (n=4 each group) and Cu concentration measured via atomic
absorption spectrometry. Values are mean ± standard deviation (SD). Significance
calculated with Student’s t-test.

Figure 2. Histologic copper localization in human temporal lobe. Histologic sections
of human brain from temporal lobe were stained with a fluorescent probe selective
for monovalent copper (CS3) and visualized by confocal microscopy.
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As we studied this phenomenon, we began hitting the technological limits
of techniques for studying neurological metallobiology. Specifically, after much
trial and error, as well as consultation with an outstanding Swiss scientist from
Georgia Tech University, we came to the conclusion that the fluorescent probe
(CS3) we had been using for imaging monovalent Cu in histologic brain sections
in fact stains lipids and might not stain Cu at all.

Dynactin p62
Despite this significant issue with Cu probes, our preliminary studies have
led to the discovery that Dynactin subunit p62, a multi-subunit protein associated
with intracellular transport that binds to ATP7B, a known Cu-binding protein, is
decreased in the brains (Figure 3) and increased in the blood (Figure 4) of AD
patients. We believe this indicates a degradation process in which p62 is broken
down in the brain and released in the blood.
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Figure 3. Dynactin p62 levels in human temporal lobe. Western blots show relative
levels of dynactin subunit p62 in temporal lobe of control, AD-only, and AD+CAA
(n=4 each group) brains. Dynactin levels normalized to beta-actin. Values are
mean ± SD.

Figure 4. Dynactin p62 in blood plasma. Blood plasma was collected from control,
MCI, AD-only, and AD+CA patients, pooled, and analyzed via LC-MS/MS.
Dynactin is a transport molecule. Values are mean number of hits per patient ±
SD.

Based on the data presented in Figures 1-4, we hypothesized that
breakdown of Dynactin p62 results in Cu transport abnormalities in the brain.
Thus, our laboratory is currently working on characterizing a number of novel,
non-commercially available monovalent Cu-staining probes that have recently
been described by laboratories at UC Berkeley as well as Georgia Tech
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University in an effort to characterize tissue and cellular level alterations in Cu in
AD and CAA. Additionally, we have attempted studies using a commercially
available siRNA system for knocking down p62 expression in neuron-like cells,
but the siRNA failed to establish knock down, and in fact increased p62
expression, albeit non-significantly. Thus, we plan to develop a p62 siRNA so we
can characterize the effects of p62 knockdown on Cu and select proteins in brain
cells like neurons, astrocytes, and microglia.

Aβ Immunotherapy
Another aspect of my early work on the involvement of Cu in AD involved
the effect of amyloid-beta (β) immunotherapy. Specifically, Elizabeth Head and
colleagues at UC Irvine were studying the effects of anti-Aβ immunotherapy on
cognitive measures in aged beagles. We obtained dog brain tissue from Dr.
Head and subsequently investigated the effects of Aβ immunotherapy on brain
Cu levels. Our hypothesis was that Aβ immunotherapy would reduce Cu levels in
the brain since Aβ has an exceptionally strong affinity for Cu. We also studied the
effects of Aβ immunotherapy in canine brains on levels of iron and zinc. We
found that there were no significant alterations in Cu or iron in dogs treated with
immunotherapy (data not shown). Large, multi-center human clinical trials
investigating the efficacy of Aβ immunotherapies in treating AD failed to
demonstrate meaningful benefit and caused significant morbidity and even
worsening of symptoms with anti-Aβ immunotherapy. These disappointing results
led to rapid and significant changes in the types of vaccines being used for
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human studies. Thus, we decided not to pursue the dog studies further since the
Aβ immunotherapies that had been used on the dogs were quickly becoming
replaced by new and improved versions that demonstrated vastly different results
than the originals.

Shift from AD and Copper to Chitosan and Nitrogen Plasma
As our laboratory was working on the aforementioned studies on AD and
Cu, we were subsequently increasing our involvement in research on a
biopolymer called chitosan (CS), pronounced kite-o-san. Our interest in CS
stemmed from Dr. Kirsch’s experience as a neurosurgeon. He was interested in
developing a novel hemostatic agent for neurosurgical operations since currently
available hemostatic agents have many negative characteristics that make
obtaining intraoperative hemostasis a highly challenging endeavor. CS is known
to have exceptional hemostatic properties – in addition to many other highly
desirable properties from a biomedical perspective – but CS-based hemostatic
agents can only be used topically.
Dr. Kirsch determined that the issue with gaining FDA approval for using
CS as an implantable hemostatic agent is inadequate methods for reducing
endotoxin contaminants in CS while simultaneously maintaining its biological
properties. Dr. Kirsch, in collaboration with Dr. Samuel Hudson from North
Carolina State University, identified non-thermal nitrogen plasma as a novel
technique that might effectively reduce endotoxin contaminants in CS without
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negatively affecting its biological properties. Thus, Drs. Kirsch and Hudson filed
and obtained a patent on the idea.
In early 2012, Dr. Kirsch obtained an SBIR grant from the NIH to study the
effects of nitrogen plasma on the hemostatic efficacy of CS in a porcine model of
laparoscopic partial nephrectomy (LPN). As a result of the funding, I switched my
focus to CS full-time from the AD and Cu work. However, by early 2013, the
relationship between Dr. Kirsch and other co-founders of the small business that
had received the SBIR grant had fallen apart and Dr. Kirsch was forced to return
the remaining funds from the SBIR grant to the NIH. Thus, my attention shifted
back to AD and Cu.
As previously described, our Cu work was not progressing due to
technical challenges. Additionally, an LLU alumnus, Dr. James Gulley, M.D.,
Ph.D., who spent time in Dr. Kirsch’s laboratory in the 1990s had visited our
laboratory and told me about work he was doing with collaborators on CS at the
National Cancer Institute (NCI) of the National Institutes of Health (NIH) where he
was the Director of Clinical Trials and Deputy Chief of the Laboratory of Tumor
Immunology and Biology. Specifically, they had demonstrated outstanding antitumor properties of CS and interleukin-12 (CS+IL-12) in the treatment of murine
bladder cancer. (Zaharoff, 2009) The NIH had been moving rapidly towards a
clinical trial to test this combination in human bladder cancer patients, but their
efforts were stymied when they were unable to obtain a sterile CS with
sufficiently low endotoxins for parenteral use and intact biologic functionality. He
was pleased to hear that we were working on solving this exact issue.
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My conversation with Dr. Gulley led Dr. Kirsch and I to begin searching for
a U.S. CS manufacturer so that we could obtain CS to sterilize and depyrogenate
with nitrogen plasma in order to move forward the implantable hemostat and
bladder cancer immunotherapy indications. We quickly identified Scion Cardiovascular, Inc. as the only U.S.-based CS manufacturer. We contacted Scion and
entered into a relationship with them. Shortly thereafter, we wrote and submitted
an SBIR grant application with the goal of characterizing the effects of nitrogen
plasma decontamination on CS with an emphasis on the preservation of its
biologic properties. We proposed to test the biologic functionality of plasmatreated CS in the same mouse model of bladder cancer that the NIH had used for
its initial studies on CS+IL-12. This SBIR grant, officially given to Scion Cardiovascular, Inc., was funded in the fall of 2014. Thus, I once again shifted my full
attention to studies on nitrogen plasma decontamination of CS and the studies
presented herein are the result of that work.

Chitosan
History and Derivation
The precursor of CS is chitin, which was first described in 1811 by a
professor of natural history in France named Henri Braconnot when he
discovered that a fraction of mushrooms are insoluble in alkaline solution. (Nwe,
2011; Muzzarelli, 2012) Braconnot named this substance “fungine.” Amazingly,
chitin was the first polysaccharide ever described. In fact, Braconnot discovered
chitin 30 years before cellulose was first described. (Muzzarelli, 2012) The name
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fungine was replaced in 1823 with “chitin” when Antoine Odier isolated a fraction
of insect cuticles (i.e. exoskeleton) that was also insoluble in basic solutions and
named it chitin after the Greek word “chiton,” meaning tunic or covering. We now
know that chitin is a highly abundant biopolymer – only surpassed in abundance
by cellulose – found in shells of crustaceans, cuticles of insects, cell walls of
fungi, and microalgae. (Nwe, 2011)
Nearly 50 years after chitin was discovered, chitosan was first described in
1859 by C. Rouget when he found that boiling insect-derived chitin in potassium
hydroxide altered it in a way that made it soluble in acids. (Baldrick, 2010;
Buschmann, 2013) F. Hoppe-Seiler then gave the name “chitosan” to this
substance in 1894. (Badawy, 2011) It took until 1950 before the chemical
structure of CS was described. (Baldrick, 2010)
In the 1970s, research into CS was stimulated by a need to control waste
generated by the seafood industry. This led to the first industrial extractions of
CS from exoskeletons of crustaceans. (Buschmann, 2013; Badawy, 2011)
Today, industrially produced chitin continues to be extracted primarily from
crustacean shells in an effort to continue controlling shellfish waste. (Nwe, 2011)
Because crustacean shell waste generated by the crab, lobster, and shrimp meat
industries is such a major environmental problem, extracting chitin and
subsequently converting it to CS is a highly economical, “green” process that is
helping ameliorate a major environmental issue. (Dutta, 2004)
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Scientific Background
Methods for isolating chitin are similar regardless of the source; the
extraction procedure generally involves deproteinization with warm NaOH,
demineralization with a strong acid like HCl, and an optional de-colorization step.
(Nwe, 2011) Chitin from different organisms varies in secondary structure. αChitin, found in crustacean shells, has a secondary structure of anti-parallel
chains and is the most abundant form of chitin in nature. β-Chitin, found in squid
beaks, forms a secondary structure of parallel chains with intrasheet hydrogen
bonding. γ-Chitin, found in cells wells of fungi, has a secondary structure with
both parallel and anti-parallel chains (i.e. both α- and β-chitin). (Jang, 2004) The
functional effects of these structural differences have not been widely
investigated, but it has been shown that α-chitin is more resistant to chemical
treatment than β- or γ-chitin due to inter-sheet hydrogen bonding. (Pillai, 2009)
The chemical structure of chitin is similar to that of cellulose with both
polysaccharides consisting of linear chains of D-glucose moieties bonded via β(1-4)-glycosidic linkages (Figure 5). The difference is chitin, with the chemical
names N-acetyl-D-glucosamine or N-acetamido-2-deoxy-D-glucopyranose, has
an acetylated amino group (–NHCOCH3) bonded at the C2 position in each Dglucose unit whereas cellulose has a hydroxyl group (–OH). CS is unique
amongst naturally occurring polysaccharides since it is basic, whereas most
others, including cellulose, are acidic. This gives CS many unique properties.
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Figure 5. Chemical structures of chitin, cellulose, and chitosan. The functional
groups at the C2 carbon are the only difference between the molecules.

CS is formed by deacetylating chitin with hot, often boiling, concentrated
NaOH. The amount of time chitin is exposed to hot NaOH dictates the degree of
deacetylation (DD) of the resultant CS. Generally, CS is defined as chitin that is
>50% deacetylated, meaning the C2 functional groups of at least half of the Dglucose units are primary amines (-NH2) (Fig. 5). (Pillai, 2009) However,
disagreement exists over naming chitin and CS based on DD and this has
generated a proposal to name chitin and CS based on acetic acid solubility.
14

(Badawy, 2011; Kumar, 2000) Of course, CS dissolves in aqueous acetic acid
and chitin does not. The former definition for CS is used in this study.
The aforementioned primary amines are positively charged and make CS
polycationic. This positive charge is responsible for virtually every advantageous
biomedical characteristic of CS, which include being biocompatible,
biodegradable, non-toxic, non-antigenic, bioadhesive, hemostatic (even in anticoagulated blood), easily manipulated, anti-oxidative, immune modulatory, an
analgesic, and a wound healing enhancer. (Bumgardner, 2003; Di Martino, 2005;
Dodane, 1999; Dutta, 2004; Khor, 2003; Lang, 1989; Nwe, 2011; Rao, 1997;
Yen, 2007; Yen, 2008) These attributes have led to investigations of a wide
range of clinical applications for CS including as a(n) drug and/or gene delivery
vehicle, immune adjuvant, pharmaceutical excipient, hemostatic agent, tissue
scaffold, and wound dressing. (Di Martino, 2005; Dutta, 2004; Enriquez de
Salamanca, 2006; Harish Prashanth, 2007; Kenaway, 2005; Khor, 2002; Khor,
2003; Kind, 1990; Mitra, 2001; Nettles, 2002; Nwe, 2011; Rao, 1997; Read,
2005; Sandri, 2004; Subar, 1992; Sugano, 1980; Vinsova, 2011; Whang, 2005;
Yen, 2008; Zivanovic, 2005)
As described previously, our laboratory’s interest in CS was sparked first
by its exceptional hemostatic properties that occur independent of the clotting
cascade via strong adhesion to negatively charged tissues and electrostatically
driven agglutination of red blood cells and platelets. (Chou, 2003; Whang, 2005)
Our interest was subsequently piqued by CS’s outstanding potential as a drug
delivery vehicle. We quickly learned that clinical uses of CS remain limited to
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topical hemostats and wound dressings in spite of CS’s outstanding biomedical
potential and the large number of CS-related publications in the biomedical
literature. We then identified inadequacy of conventional sterilization methods for
sterilizing and especially depyrogenating CS as the primary reason for limited
clinical use of CS. These conventional sterilization methods include dry/wet heat,
radiation, and chemical sterilants and they cause alterations such as
caramelization of the polysaccharide, chain scissions, and/or may leave residual
toxic residues in the material. (Whang, 2005; de Oliveira Cardoso Macedo, 2013;
Franca, 2013; Lim, 1998; Lim, 1999; Marreco, 2004; Norzita, 2013; Rao, 1995;
Rosiak, 1992; San Juan, 2012) These alterations to the physical and chemical
properties of CS cause changes in the biological properties as well. Thus, these
methods are not optimal, or appropriate, for sterilizing CS. We hypothesized that
non-thermal nitrogen plasma would effectively sterilize and depyrogenate CS and
the biological properties of CS would simultaneously be preserved.

Plasma
Scientific Background
Plasma is the oft forgotten 4th state of matter – after solid, liquid, and gas –
and has emergent properties that gases do not such as conductivity, magnetism
and quasi-neutrality. (Cornelius, 2007) Ironically, 99% of the matter in the
universe is in the plasma state since most stars in the universe, including Earth’s
sun, primarily consist of plasmas. (Tendero, 2006) These extraterrestrial plasmas
are fully ionized and therefore consist entirely of ionized gas molecules and
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electrons. (Moisan, 2001) Due to their very high temperatures (5,000-10,000
Kelvin), these plasma are termed hot plasmas. (Yokoyama, 1990)
On Earth, the most common forms of naturally occurring plasmas include
lightning and auroras (borealis/australis). (Moisan, 2001; Shintani, 2007) Many
artificially generated plasmas have become commonplace as well, especially in
industries such as the aeronautical sector (e.g. plasma arc welders, a hot
plasma) and microelectronics/semiconductor sector (e.g. low pressure cold
plasma for altering material surfaces). (Tendero, 2006) To generate a plasma,
the kinetic energy of the molecules of a gas must exceed their ionization energy.
Once this occurs, the outer-most electron exits the electron cloud thereby making
the atom positively charged. Although an ion has formed, there is no overall
charge of the plasma because the parent species, the gas, was uncharged. This
is called the principle of quasi-neutrality; there are areas of positive charge (ions)
and negative charge (electrons), but overall the charges are equal and the
plasma is not charged. (Cornelius, 2007)
For medical applications of plasma, a ”cold,” or non-thermal plasma,
generally defined as having a temperature ≤ 40°C, is desired. (Kong, 2009) Nonthermal plasmas consist of only partially ionized gas. Thus, non-thermal plasmas
contain ionized gas molecules, free electrons, free radicals, neutral byproducts,
and photons. Such plasmas are generated with a weak electric field. (Moisan,
2001; Messerer, 2005; Morfill, 2009) The number of excited, or hot, atoms and
molecules is small enough that the heated gas species and their derivatives (i.e.
electrons) quickly collide with non-excited, or “cold,” gas molecules. These
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collisions de-excite and resultantly cool the excited species. When this occurs,
photons are emitted. In the case of plasma generated from nitrogen gas, called
non-thermal nitrogen plasma (NtNP), a rapidly pulsed electric field can be used
to generate the plasma because ionization of nitrogen species occurs rapidly via
Townsend discharge, a form of electron avalanche where excited electrons
collide with non-excited atoms causing more electrons to ionize, which then
collide with more non-excited atoms. (Massines, 2005)

Plasma Decontamination
Many studies have demonstrated plasma effectiveness in killing or
inactivating bacteria, bacterial spores, viruses, fungi, pyrogens, and prions.
(Claire, 2006; Deilmann, 2008; Ehlbeck, 2011; Kelly-Wintenberg, 1998; Klampfl,
2012; Kong, 2009; Koulik, 1999; Kvam, 2012; Laroussi, 1996; Laroussi, 2005;
Messerer, 2005; Mogul, 2003; Moisan, 2001; Rauscher, 2010; Rossi, 2009;
Shintani, 2007; Sureshkumar, 2010; Ulbin-Figlewicz, 2014; Vicoveanu, 2008;
Yang, 2009) As such, non-thermal plasma has been used in food processing and
beverage bottling to sterilize plastics in an economical manner. (Adler, 1998;
Deilmann, 2008; Messerer, 2005) However, the only plasma systems that have
been employed in the medical field are “plasma-assisted” devices in which a
germicidal gas vapor, usually hydrogen peroxide or formaldehyde, are ionized in
order to enhance the microbicidal properties of the vapor. (Laroussi, 2005;
Okpara-Hofmann, 2005) It is noteworthy that plasma-assisted hydrogen peroxide
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sterilization is thought to sterilize via oxidation, a different mechanism than true
gas plasmas. (Krebs, 1998; Lerouge, 2000)
The mechanisms by which plasmas inactivate spores and other biological
molecules like endotoxins and prions are debated, but it is agreed that UV plays
a significant role in spore inactivation, as does chemical etching. Studies have
shown that there is a triphasic effect of plasma on bacterial spores. During the
first phase, which is fast, it is postulated that UV radiation, through DNA damage,
inactivates the first layer of spores on a surface. During the second phase, which
is much slower, etching takes place. During this process, layers of spores are
physically “etched” away by bombardment of the surface with charged particles
and synergistic reactions of active species with the surface molecules of the
material being treated. The third phase, which is fast like the first, is thought to be
when the last monolayer of spores are inactivated by UV radiation. (Rauscher,
2010; Klampfl, 2012; Kvam, 2012; Moisan, 2001; Vicoveanu, 2008; Von Keudell,
2010) For pyrogens, studies suggest that the inactivation occurs via physicochemical interactions with reactive species in the plasma that result in either
chemical alterations to the molecules rendering them unrecognizable by immune
cells or physical degradation through etching that ultimately leads to volatility
and, thus, removal from the material. (Von Keudell, 2010)
NtNP has been shown to be the most efficient, least material damaging
plasma in terms of sterilization and depyrogenation because nitrogen gas is
difficult to energize to atomic nitrogen. (Shintani, 2007) Thus, we focused our
studies on nitrogen-based non-thermal plasmas. Our studies presented herein
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represent the largest characterization of NtNP sterilization and depyrogenation of
medical devices or pharmaceuticals to date.

Plasma Treatment of Chitosan
To our knowledge, there are no reports in the literature of sterilization and
depyrogenation of CS with NtNP or any other type of plasma. The reports on
plasma treatment of CS that do exist focus on surface modifications induced by
plasma treatment. For example, in a study by Silva et al, CS films were treated
with nitrogen and argon plasmas and changes in physico-chemical properties
were characterized. (Silva, 2008) They went on to determine the effect of the
physico-chemical changes on the biological properties of CS. Similar studies
have examined the physico-chemical changes to CS films induced by H2, NH3,
He/NH3, and argon plasmas. (Ogino, 2008; Wanichapichart, 2009) Another study
examined how argon, methane, and oxygen plasmas affect the anti-microbial
properties of CS. (de Oliveira Cardoso Macedo, 2013) One study, by Luna et al,
showed that NtNP treatment increased cell adhesion to CS. (Luna, 2011) This
led us to hypothesize that NtNP treatment would enhance the hemostatic and
drug delivery properties of CS by increasing its bioadhesivity.

The Present Research
The present studies sought to characterize the physico-chemical and
biological effects of NtNP decontamination of CS. Our goal was to enable new
clinical applications of CS that have been hindered by the inadequacy of
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conventional sterilization methods in decontaminating CS. The studies were
intended to serve as the pre-clinical foundation necessary for the
commencement of human safety tests of CS as an implantable material. Two
major clinical applications of CS were targeted in our studies. First, we sought to
demonstrate that NtNP-sterilized CS is safe and effective as a drug delivery
vehicle. Second, we sought to demonstrate that NtNP-sterilized CS maintains its
hemostatic efficacy and can be safely implanted.
A secondary goal of the project was to advance development of NtNP as a
sterilization and depyrogenation procedure for thermolabile polymers. These
materials are becoming increasingly utilized in medical products and require
improved sterilization techniques.

Approach of the Studies
For all of the studies, raw CS flake was obtained from Scion Biomedical,
Inc. The CS Scion manufactured is a medical-grade CS derived from crab shells
from one haul of one fishing boat. All NtNP treatments were performed on either
a low-pressure plasma (LpP) instrument manufactured and operated by PVATePla America, Inc. or an atmospheric pressure plasma (ApP) instrument built
and operated by the Department of Nuclear Engineering at North Carolina State
University. The majority of the plasma treatments were performed on the LpP
system due to concerns regarding the age, consistency, and durability of the ApP
system. Additionally, since this project was focused on translatability of the
research results, the commercial availability of the LpP system was viewed as a

21

major advantage over the ApP system. Prior to the commencement of these
studies, there were no definitive results that had been published showing that
either type of plasma, LpP or ApP, was superior at achieving sterilization and
depyrogenation. (Klampfl, 2012; Koulik, 1999; Laroussi, 1996)

Study 1
Since the raw Scion CS was in a flake form and NtNP is only a surface
treatment, we first micronized the CS into a powder via a cryo-milling technique
to increase its surface to volume ratio and improve its solubility. Two cryo-milling
techniques were analyzed and the physico-chemical properties of CS were
characterized before and after milling (Study 1). The effect of NtNP sterilization
on the physico-chemical properties of the CS flake and powder were then
determined.

Study 2
Once a sterile CS powder was generated via NtNP treatment,
preservation of the biological properties of the CS was characterized in a mouse
model of bladder cancer. This model was chosen based on the results of a
previous pre-clinical study performed at the NCI in which it was found that CS
drastically enhanced the anti-tumor efficacy of interleukin-12 (IL-12) in a murine
orthotopic bladder cancer model. (Zaharoff, 2009) The NCI prepared a phase I
human clinical trial based on the results of this study, but it was stymied by an
inability to obtain a sterile CS with sufficiently low endotoxins and intact biologic
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functionality. Thus, we reasoned that if NtNP-sterilized CS+IL-12 demonstrated
similar anti-tumor properties as the NCI observed, the phase I trial could move
forward. Since intravesical administration of drugs into the bladder is considered
a parenteral route of administration, but there is limited direct contact with the
blood, we reasoned that initially testing a parenteral preparation of CS in the
bladder would be an exceptionally safe approach.

Study 3
In Study 3, we shifted our attention to the hemostatic properties of CS.
There has been immense interest in developing CS as a hemostatic agent since
1983 when Mallette and colleagues discovered that CS could induce a rapid
coagulum in both normal and anti-coagulated blood. (Malette, 1983) This is
reflected in the large number of 100% CS topical hemostatic agents currently on
the market. However, not a single implantable CS hemostatic agent has been
approved for human use. The primary barriers preventing approval of implantable
CS hemostatic agents include pyrogen levels that exceed regulatory limits and
insufficient evidence demonstrating CS is safe to implant.
For Study 3, Scion’s FDA approved topical hemostatic agent (Clo-Sur
P.A.D.™), which consists of a lyophilized CS pad, was sterilized with NtNP and
its hemostatic efficacy subsequently evaluated in an established rat model of
bleeding. (Ersoy, 2007) Unsterilized and electron beam (EB) sterilized pads were
used as controls to evaluate whether NtNP sterilization had a negative effect,
positive effect, or no effect on the hemostatic properties of CS. Effect of NtNP
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sterilization on select physico-chemical properties of the pads were also
characterized.

Study 4
For study 4, NtNP-sterilized pads were tested in a porcine LPN model of
bleeding. For this model, the lower pole of one kidney was removed using a
laparoscopic approach. CS was then used as the sole hemostatic agent for
achieving hemostasis. EB sterilized pads were used as the benchmark for
evaluating the effect of NtNP sterilization on the hemostatic properties of CS.
Hemostatic effectiveness was determined by the number of pads needed to
achieve hemostasis, estimated blood loss (EBL), and warm ischemia time. The
animals were then monitored for complications for 14 weeks and histologic
examinations were performed to evaluate the surgical site with the implanted CS
for presence of urinoma, hematoma, degree of CS resorption, and tissue
reactivity. We hypothesized that the NtNP-sterilized CS would have superior
hemostatic properties and tissue compatibility compared to the ES-sterilized CS.

Significance of the Studies
As discussed previously, CS has numerous potential parenteral uses
including as a(n) resorbable hemostatic agent, immune adjuvant, and drug or
gene delivery vehicle. Overcoming the primary barrier that has prevented these
applications from achieving clinical use would represent a major advancement.
As such, a sterile CS with endotoxin levels below the regulatory mandates for
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parenteral drugs and Class III medical devices with intact biological properties
will enable immediate clinical testing of CS as a drug delivery vehicle and
implantable hemostatic agent. For example, the NCI will be able to move forward
with a phase I clinical trial testing the safety and efficacy of CS+IL-12 for the
treatment of non-muscle invasive bladder cancer. Since other murine tumors
have also shown responsiveness to CS+IL-12, human trials for these other
malignancies could also commence. Additionally, wide availability of a
pharmaceutical-grade, sterile/depyrogenated CS would potentially eliminate, or
at least reduce, the inflammatory and immunologic artifacts secondary to
endotoxin contamination that plague pre-clinical studies of CS. (Gorbet, 2005;
Lieder, 2013)
The significance of an effective new treatment for urinary bladder cancer
(BC) cannot be understated. BC is the 5th most common cancer in the US with
over 70,000 new cases diagnosed each year. It is also the most expensive
cancer to treat per patient due to high recurrence rates. (Jemal, 2010; Siegel,
2012; Siegel, 2013; Siegel, 2011; Van Der Heijden, 2009; van Rhijn, 2009) Over
90% of BC cases are transitional cell carcinomas (TCC) and 80% of TCCs are
classified as superficial, or more appropriately non-muscle invasive, tumors
(stages Ta, Tis, or T1). (Kirkali, 2005; Pasin, 2008) Notably, it has been over 30
years since a new treatment for non-muscle invasive BC was approved. (Jarow,
2014) The current standard of care for non-muscle invasive BC is transuretheral
resection (TUR) of the tumor with post-operative immunotherapy provided by
inducing an intravesical infection with bacillus Calmette-Guerin (BCG).
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(Askeland, 2012; Hall, 2007) Between 20-30% of patients do not respond to BCG
therapy and 20-50% of BCG-responsive patients develop recurrent tumors within
5 years. (Parkin, 1999; Malmstrom, 1999; Van Der Heijden, 2009; van Rhijn,
2009)
As with BC, an implantable hemostatic agent could have a tremendous
clinical impact. Hemostasis remains a significant challenge in many surgical
operations and traumas. An economical, resorbable hemostatic agent that
retains its effectiveness in the presence of anti-coagulant therapy would greatly
improve the management of intraoperative hemostasis. (Whang, 2005)
Finally, there will be many uses for a sterilization/depyrogenation
technique like NtNP in medicine. Many delicate materials are increasingly being
used for medical devices and traditional sterilization methods either reduce the
effectiveness and/or durability of the devices or preclude their use entirely. Thus,
an effective decontamination technique that retains the physico-chemical
properties of such materials would be widely used. Replacing techniques that
use highly toxic compounds like ethylene oxide and formaldehyde would improve
the safety for workers that must routinely sterilize medical supplies.
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Abstract
Chitosan has great potential as a pharmaceutical excipient. In this study,
chitosan flake was micronized using cryo-ball and cryo-jet milling and
subsequently sterilized with nitrogen plasma. Micronized chitosan was
characterized by laser diffraction, scanning electron microscopy (SEM),
conductometric titration, viscometry, loss on drying, FTIR, and limulus amebocyte
lysate (LAL) assays. Cryo-jet milling produced mean particle size of 16.05 μm,
44% smaller than cryo-ball milling. Cryomilled chitosan demonstrated increased
hygroscopicity, but reduced molecular weight and degree of deacetylation (DD).
SEM imaging showed highly irregular shapes. FTIR showed changes consistent
with reduced DD and an unexplained shift at 1100 cm -1. Plasma treated chitosan
was sterile with <2.5 EU/g after low-pressure plasma and <1.3 EU/g after
atmospheric pressure plasma treatment. Plasma treatment decreased the
reduced viscosity of chitosan flake and powder, with a greater effect on powder.
In conclusion, pharmaceutical grade, sterile chitosan powder was produced with
cryo-jet milling and plasma sterilization.

Keywords: Chitosan, Cryomilling, Jet Milling, Ball Milling, Cryo-ball Milling, Cryojet milling, Plasma Sterilization

Abbreviations: CS – chitosan; NtNP – non-thermal nitrogen plasma; ApP –
atmospheric pressure plasma; LpP – low-pressure plasma; DD – degree of
deacetylation;
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Introduction
Chitosan (CS) in the presence of moisture is a soft, ductile biopolymer
with great potential as a biomedical material, especially as an excipient and
immune adjuvant. CS is obtained commercially by deacetylating chitin extracted
from either crustacean shells via chemical extraction or fungi via enzymatic
extraction and consists of β-1,4-linked 2-amino-2-deoxy-D-gluocopyranose and
N-acetamido-2-deoxy-D-glucopyranose moieties that are randomly distributed
throughout the polymer chain. Since chitin is the second most abundant
biopolymer on Earth and crustacean shell waste generated by the seafood
industry is an environmental problem in coastal areas, CS is a widely available,
green, and economical biomaterial. Chitin becomes CS once at least 50% of the
D-glucosamine moieties in the polymer chain are deacetylated (Pillai, Paul &
Sharma, 2009). However, there is disagreement over the naming of chitin and
CS based on degree of deacetylation, which has resulted in a proposal for
naming chitin and CS based on solubility in acetic acid (Badawy & Rabea, 2011;
Kumar, 2000). CS is soluble in aqueous acetic acid, whereas chitin is not.
As an excipient, CS enhances drug penetration through tissues and
epithelial barriers by loosening gap junctions, maintains drug in the area of
interest through bioadhesion between cationic amino groups of CS and anionic
tissues, and controls drug release over time by keeping drugs bound until
physical degradation (Artursson, Lindmark, Davis & Illum, 1994; Dodane, Amin
Khan & Merwin, 1999; Jameela, Misra & Jayakrishnan, 1994; Kristl, ŠmidKorbar, Štruc, Schara & Rupprecht, 1993; Luessen, de Leeuw, Langemeyer, de
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Boer, Verhoef & Junginger, 1996; Nordtveit, Vårum & Smidsrød, 1994; Schipper,
Vårum & Artursson, 1996; Takeuchi, Yamamoto, Niwa, Hino & Kawashima,
1996; van der Lubben, Verhoef, van Aelst, Borchard & Junginger, 2001). The
biological functions of CS are dependent on its physical properties, including
molecular weight (MW), degree of deacetylation (DD), salt form, and pH at which
it is used (Dodane & Vilivalam, 1998; Kumirska, Weinhold, Thöming &
Stepnowski, 2011). This physical-functional relationship necessitates careful
characterization of CS formulations. Since powder and hydrogel forms of CS –
especially those composed of particles in the low micron range – have been
identified as the ideal form of CS for pharmaceutical applications and
micronization of materials is a common process in pharmaceutical
manufacturing, the goal of the present study was to formulate and characterize a
pharmaceutical grade CS powder that can also serve as a precursor to a
hydrogel when dissolved in dilute acids (van der Lubben, Verhoef, van Aelst,
Borchard & Junginger, 2001).
A powder form of CS was also desired to enhance the effectiveness of a
novel sterilization method for CS based on non-thermal nitrogen gas plasma
(NtNP) (de Oliveira Cardoso Macedo, de Macedo, Gomes, de Freitas Daudt,
Rocha & Alves, 2013). Plasma is considered the fourth state of matter and
consists of an ionized gas that has emergent properties the gas alone does not,
such as magnetism and conductivity. Use of NtNP for sterilization of CS is
necessitated by the fact that conventional sterilization methods like dry/wet heat,
radiation, and chemical sterilants cause caramelization of the polysaccharide,
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chain scissions, and/or may leave residual toxic residues in the material (de
Oliveira Cardoso Macedo, de Macedo, Gomes, de Freitas Daudt, Rocha & Alves,
2013; Franca et al., 2013; Lim, Khor & Koo, 1998; Lim, Khor & Ling, 1999;
Marreco, da Luz Moreira, Genari & Moraes, 2004; Norzita, Norhashidah,
Maznah, Nurul Aizam Idayu Mat, Nor Akma & Norafifah Ahmad, 2013; Rao &
Sharma, 1995; Rosiak, Ulański, Kucharska, Dutkiewicz & Judkiewicz, 1992; San
Juan et al., 2012). These physicochemical changes result in changes in the
biologic properties of CS making these methods non-optimal for sterilizing CS.
Since NtNP is a surface treatment, it benefits from a large surface to volume
ratio, which is accomplished when a material is micronized.
Knowledge on micronizing hard and crystalline materials is extensive, but
lacking on softer materials. It is vital to characterize particle size and size
distribution of powders since these properties influence flowability, dissolution,
release kinetics, and more (Koennings, Sapin, Blunk, Menei & Goepferich, 2007;
Miranda, Millán & Caraballo, 2007; Mullarney & Leyva, 2009). Reports in the
literature of techniques for generating micronized CS powders are especially
sparse. Techniques for micronizing CS that have been reported include dense
gas anti-solvent precipitation, supercritical-assisted atomization, microsphere
precipitation, high speed planetary ball mill, and ultrafine milling (Chien, Li, Lee &
Chen, 2013; Gimeno, Ventosa, Boumghar, Fournier, Boucher & Veciana, 2006;
Reverchon & Antonacci, 2006; Yao, Peng, Yin, Xu & Goosen, 1995; Zhang,
Zhang, Jiang & Xia, 2012; Zhang, Zhang & Xia, 2014). We identified cryomilling
as an optimal method for generating a CS powder based on previous studies that
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show it preserves functional properties of proteins and starches by reducing the
energy input needed to fractionate particles into smaller sizes (Dhital, Shrestha,
Flanagan, Hasjim & Gidley, 2011; Ehmer, 2010; Tran, Shelat, Tang, Li, Gilbert &
Hasjim, 2011). Additionally, cryomilling overcomes the soft ductile nature of CS,
which reduces the effectiveness of traditional milling techniques in micronizing
soft materials like CS (Garmise et al., 2006; Saleem & Smyth, 2010).
In the present study, two cryomilling techniques were tested, cryo-jet and
cryo-ball milling. Ball and jet mills were chosen for this study since they are the
only milling machines commonly used to reduce particles to 5 μm or less in dry
conditions. (Vatsaraj et al 2003) Both ball and jet mills are thought to reduce
particle sizes using the same mechanism(s), which is by breaking particles along
cracks or fractures that already exist at the micro- or nanoscale. Although jet
milling is the most commonly used technique for producing particles in the lower
micrometer range and is the gold standard for manufacture of inhalable particles
of small molecular drugs, this study is the first reported use of cryo-jet milling for
micronizing CS (Ehmer, 2010). Once the optimal CS powder formulation was
identified, defined as the micronized powder with the smallest mean particle size,
it was sterilized with NtNP to form a sterile, pharmaceutical grade CS powder.
Physicochemical properties of the CS were characterized before and after both
milling and NtNP sterilization.
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Materials and Methods
Reagents
All chemical reagents including glacial acetic acid, lactic acid, sodium
acetate, hydrochloric acid, sodium hydroxide, and tryptic soy agar were obtained
from Sigma Aldrich or Fisher Scientific and were of analytical grade.

Cryomilling
CS derived from crab shells in the form of 1-10 mm flakes was obtained
from Scion Biomedical, Inc. (Miami, FL). CS flakes were filtered with fine mesh to
remove flakes > 8 mm in diameter and approximately 30 g of filtered CS flake
was placed in a 25 mL zirconium oxide jar. Six milling balls made of either
zirconium oxide (10 mm diameter) or stainless steel (5 mm) were added to the jar
and the CS flakes were subsequently milled under cooling with liquid nitrogen at
30 Hz for up to 30 minutes in the Retsch CryoMill system (Verder Scientific, Inc.,
Newtown, PA). For cryo-jet milling, CS flakes were filtered, as described above,
to remove flakes > 8 mm, 470 g of filtered CS was placed in the Micron-Master
jet pulverization system (The Jet Pulverization Co., Inc., Moorestown, NJ), cooled
with liquid nitrogen, and milled with a jet stream of liquid nitrogen for 30 minutes.

Particle Sizing
Particle size analyses were performed on powders by suspending CS in
water and measuring particle size with a Horiba LA-930 laser diffraction analyzer
(HORIBA Instruments, Inc., Irvine, CA).
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Degree of Deacetylation
Degree of deacetylation (DD) of both CS flake and powder was
determined by conductometric titration. Conductometric titration was performed
by dissolving dried CS sample of known mass (about 0.100 g) into 10 mL of 0.1
N hydrochloric acid (HCl) then 90 mL of distilled water. The CS solution was then
titrated with a standard 0.1 N sodium hydroxide (NaOH) solution using a 10 mL
buret while the solution conductivity was monitored as a function of the volume of
NaOH added with an Orion Benchtop Conductivity Meter (Model 162) equipped
with an Orion Conductivity Cell (Model 013030) (Raymond, Morin &
Marchessault, 1993). During the titration, the temperature of the solution was
kept constant (30 ˚C) by using a water bath since the conductivity is a function of
temperature. In a typical conductometric titration curve, there are two deflection
points. The first deflection point corresponds to the neutralization of excess H +
ions of the strong acid, HCl. After all excess H+ ions are neutralized, then the
neutralization of the weak acid, the ammonium salt in CS, starts. After the
ammonium is completely neutralized, the conductivity again goes up with a
higher value of slope due to the excess of OH- ions of NaOH added, which is the
second deflection point. Thus, the range between the first and the second
deflection points corresponds to the neutralization of the protonated amine
groups of CS. As a result, the number of moles of NaOH used between the first
and second deflection points equals the number of moles of amine groups of the
CS sample. The percent DD was calculated by the following equation:
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%DD =

(𝑣2−𝑣1) × 𝑀𝑁𝑎𝑂𝐻 (

𝑚𝑜𝑙
161.16𝑔
)×
𝐿
𝑚𝑜𝑙

𝑀𝑎𝑠𝑠 𝑜𝑓 𝑐ℎ𝑖𝑡𝑜𝑠𝑎𝑛 𝑠𝑎𝑚𝑝𝑙𝑒 (𝑔)

× 100

(1)

where (v2-v1) is the difference in volume in liters between the two deflection
points, MNaOH is the molarity (mol/L) of standard NaOH solution, and 161.16 is
the molar mass of chitosan.

Morphologic Characterization
CS particles were imaged via scanning electron microscopy (SEM) using
a Phenom G1 (Model 800-03103-02) (FEI Co., Netherlands) microscope. Prior to
imaging, a small amount of CS powder or flake was fixed on conductive carbon
tape and mounted on the support. The sample was then sputtered with an
approximately 6 nm layer of gold/palladium (Au/Pd) using a Quorum
Technologies SC7620 Mini Sputter Coater (Laughton, East Sussex, UK), which
deposits 10 nm coating/45 sec.

Hygroscopicity
Hygroscopicity of CS flake and powder was measured by loss on drying
using a 120VAC Moisture Balance IL-50.001 (Summit Measurement Inc., South
Deerfield, MA), an automatic moisture balance with a capacity of 50 g and
resolution of 0.001 g. CS samples were placed on the balance and the masses
before and after drying via vacuum were recorded. Loss on drying was calculated
as the percent difference between the initial and final mass.
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Molecular Weight
Viscosity of CS samples was measured using a 2-10 centistoke glass
capillary ASTM 1 Ubbelohde viscometer (Fisher Scientific, Pittsburgh, PA).
Viscosity measurements were performed by dissolving chitosan in a solvent
containing 0.3 M acetic acid and 0.2 M sodium acetate (0.3 M AcOH/0.2 M
NaOAc) to a final CS concentration of 1-2 mg/mL (0.1%-0.2%). The AcOH
protonates the amino group which solubilizes CS and the NaOAc salt screens
electrostatic interactions between different CS chains. The 0.3 M AcOH/0.2 M
NaOAc solvent was chosen since previous studies have shown it prevents
aggregate formation, unlike other solvents like 0.1 M AcOH/0.2 M NaCl
(Rinaudo, Milas & Dung, 1993; Roberts & Domszy, 1982). Efflux times were
measured for each of 3 concentrations (1 mg/mL, 1.5 mg/mL, and 2 mg/mL) and
the following viscosities were determined using the given equations:

𝑡

Relative viscosity

nrel = 𝑡 𝐶𝑆

(2)

Specific Viscosity

nsp = nrel-1

(3)

𝑠𝑜𝑙

Reduced viscosity nred =

𝑛𝑠𝑝

(4)

𝑐

where tCS represents efflux time for chitosan, tsol represents efflux time for the
solvent, and c represents chitosan concentration in g/mL. Intrinsic viscosity ([n])
was calculated using the Huggins plot in which the reduced viscosities for the 3
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chitosan concentrations were extrapolated to infinite dilution (i.e. zero
concentration). Intrinsic viscosity is related to molecular weight by the MarkHouwink equation:

[n] = KMα

where K and a are constants for the specific polymer, solvent, and temperature
combination. The K and a values for CS with a %DD of approximately 80% and
the solvent 0.3 M AcOH/0.2 M NaOAc at 25 ˚C are 0.074 and 0.80, respectively
(Brugnerotto, Desbrières, Roberts & Rinaudo, 2001).

FTIR
Molecular composition of CS flake and powder was assessed via Fourier
Transform Infrared Spectroscopy (FTIR). To generate FTIR spectra, films of CS
salts were cast by dissolving the CS flake or powder in 1% acetic acid. The films
were then converted to the free amine form of CS by washing films in alcoholic
base prior to imaging with a Nicolet iS50 FT-IR instrument (Thermo Fisher
Scientific, Madison, WI) using a diamond attenuated total reflectance (ATR)
attachment and 32 scans at 4 cm-1 resolution.

Plasma Sterilization
CS samples were sterilized via NtNP treatment with either atmospheric
pressure plasma (ApP) or low-pressure plasma (LpP) systems. The ApP
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instrument is a custom built instrument housed at North Carolina State University
that has been described in detail previously and was operated at 4.8 kW power
and 5 kHz frequency (Cornelius, 2007). Helium was used as the carrier gas at a
flow rate of 10 L/min. The LpP instrument is the IoN40 plasma system (PVATePla America, Corona, CA) and the gas used was medical grade nitrogen,
power was 500 Watts, pressure was maintained at 300 mTorr, and gas flow was
0.5 L/min.
Prior to NtNP treatment, CS samples were weighed and placed into
paper-backed sterilization pouches. The pouches used in the ApP instrument
were sealed and subsequently flushed with 100% nitrogen gas whereas the
pouches used in the LpP instrument were left unsealed. The CS-containing
pouches were placed into the ApP instrument or directly on the metal tray of the
IoN40. For the LpP, the chamber was evacuated down to <100 mTorr and
flushed with 100% nitrogen gas 3 times prior to beginning the NtNP treatment.
Evacuating and flushing the chamber served to ensure the CS-containing
pouches were filled completely with 100% N2 gas instead of air.
Previous studies showed that sterility doses, defined as a 6-log reduction
in bacterial spores, were achieved at 15 mins with both the ApP and LpP
instruments when using nitrogen gas. As is commonly done in medical device
and pharmaceutical manufacturing, an overkill dose of 2X the sterility dose, 30
minutes in this case, was used in these studies. Sterility of each NtNP-treated CS
sample was confirmed by diluting each sample 40X with pyrogen-free water to
overcome the anti-microbial properties of CS and subsequently cultured in
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standard polystyrene petri dishes containing tryptic soy agar at 37°C for 72
hours. Colony-forming units were enumerated by manually counting each culture
plate.

Endotoxins
Endotoxins are measured in endotoxin units (EU), a unit of biological
activity based on the United States Pharmacopoeia Reference Endotoxin
Standard, since different types of endotoxins elicit varying degrees of immune
responses. Endotoxins were extracted from CS by incubating CS samples in a
40X volume of pyrogen-free water (w/v) for 2 hours at 37°C. The extracts were
then syringe filtered through a 0.22 μm mixed cellulose esters filter to remove
any residual CS that can cause false positives with Limulus amebocyte lysate
(LAL) assays. The endotoxin concentration in the filtrate was subsequently
quantitated using a handheld LAL device (Endosafe PTS device, Charles River
Laboratories, Charleston, South Carolina) and FDA-certified 0.5-0.005 EU/mL
PTS cartridges. The LAL assay is the current gold standard method for
quantitating endotoxins in drugs and medical devices.

Results and Discussion
Particle Size Analysis
Cryomilling raw CS flake with either a cryo-ball or a cryo-jet mill resulted in
a fine, white powder, as shown in Figure 6, consisting of mostly <100 μm
particles. Average particle size and size distribution, including median and the
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diameter larger than 95% of the particles (D95), for each milling machine and
parameter are presented in Table 1. Cryo-ball milling CS flakes for 15 minutes
with 10 mm zirconium oxide balls generated CS powder with the largest mean
particle size. Doubling the grind time to 30 minutes reduced the mean particle
size by 21% and D95 by 15%. Using 50% smaller stainless steel balls reduced
the mean particle size and D95 by an additional 57% and 55%, respectively. The
smallest mean particle size generated by cryomilling (28.5 μm) was 24% smaller
than the mean particle size generated by a standard ball mill after 8 hours (37.53
μm) in a previous study (Zhang, Zhang & Xia, 2014).

Figure 6. Macroscopic images of CS flake (left) and cryo-jet milled powder (right).
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TABLE 1. Mean, Median and D95 values for cryomilled chitosan.
Mean

Median

D95

Cryo-ball Mill (10
mm balls; 15 mins)

84.5 μm

71.0 μm

209.7 μm

Cryo-ball Mill (10
mm balls; 30 mins)

66.8 μm

52.2 μm

179.0 μm

Cryo-ball Mill (5 mm
balls; 30 mins)

28.5 μm

20.4 μm

80.3 μm

Cryo-jet Mill (30
mins)

16.05 μm

15.62 μm

24.24 μm

Cryo-jet milling CS for 30 minutes produced the smallest particles, with a
mean particle size (16.05 μm) that was 44% smaller than the smallest mean
particle size produced by cryo-ball milling (28.5 μm). Although the cryo-jet mill
proved to be the superior method for milling CS into powder in the present study,
a previous study showed that CS powder with a particle size distribution similar
to cryo-jet milling can be produced with a cryo-ball mill when coupled with
thermocatalytic destruction of CS (Laka & Chernyavskaya, 2006). Furthermore,
another study found that CS flakes can be reduced to submicron sizes using an
ultrafine milling technique (Zhang, Zhang, Jiang & Xia, 2012).

Viscosity and Molecular Weight
Cryomilling reduced the intrinsic viscosity and molecular weight (MW) of
CS as shown in Figure 7. This reduction is a result of scissions of the chitosan
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polymer chain. A detailed discussion of this mechanism is provided in section
3.5. Since MW has a dramatic influence on the biological properties of CS,
additional studies are needed to understand the influence of powders with
different particle size distributions on biologic properties (Kumirska, Weinhold,
Thöming & Stepnowski, 2011).

Figure 7. Effect of cryo-jet milling on intrinsic viscosity (A) and molecular weight
(B) of CS. Flake is raw CS and powder is milled CS. Values in A are the intrinsic
viscosity (measured in centistokes (cSt)) calculated as the y intercept at zero
concentration of the reduced viscosities of 3 CS concentrations. Values in B are
the MW of CS calculated by the Mark-Houwink equation.

Degree of Deacetylation
Changes in the DD are shown in Figure 8. The 9.6% reduction in DD after
cryo-jet milling appears to be another consequence of the scissions in the CS
polymer chain that occur during cryomilling. Specifically, we postulate that chain
breaks lead to changes in functional groups in CS that may lead to chemical
reactions. However, other mechanisms are possible. For example, high
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temperatures are known to occur, albeit for very short times (< 10-6 seconds), at
the fracture sites during cryo-jet milling and this might cause slight caramelization
of the CS (Rumpf, 1973; Weichert & Schönert, 1976). Thus, additional studies
are needed to better understand the mechanism(s) responsible for this change in
%DD with cryomilling.

100%

Percent Degree of
Deacetylation

90%
80%
70%
60%

Flake

50%
Powder

40%

30%
20%
10%
0%

Figure 8. Effect of cryo-jet milling on degree of deacetylation of CS. Flake is raw
CS and powder is milled CS. Values represent degree of deacetylation expressed
as a percent off all the glucosamine moieties comprising the CS polymer.

Hygroscopicity
The hygroscopicity of CS was increased by 25% after milling with loss on
drying of the cryo-jet milled CS at 11.12% compared to 8.34% for the CS flake,
reflecting the increase in surface area of the cryomilled material. The increase in
hygroscopicity of CS after cryomilling is similar to the % loss on drying for the
thermocatalytic ball milled CS powder reported by Laka and Chernyavskaya. The
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high hygroscopicity of CS powder must be taken into account when making CS
solutions, which are commonly used for biomedical, and especially
pharmaceutical, applications (Ahmadi, Oveisi, Samani & Amoozgar, 2015;
Heffernan, Zaharoff, Fallon, Schlom & Greiner, 2011).

Morphologic Characterization
Morphologic characterization of the micronized CS via SEM imaging
showed highly irregular particle shapes after cryo-jet milling, as shown in Figure
9. These irregular particle shapes are thought to be a result of the fact that most
polymers at room temperature exhibit considerable tensile toughness or work to
rupture, compared to glassy, brittle materials such as inorganic glasses. The
appearance of the milled CS suggests the CS flakes are torn apart in a random
fashion, leaving highly diverse particle shapes and sizes. The majority of
particles appeared either sphere-like or spindle shaped. The size of these
shapes is small enough that individual polymer chains are likely broken in the
milling process, which leads to the reduced intrinsic viscosity and MW shown in
Figure 7. For example, if we take 5.15 x 10-10 m as the diameter of the
glucopyranose sugar ring, and assume that there is a degree of polymerization of
1000, then the CS chain is 0.5 μm in length and the particles range in diameter
down to 16 μm and smaller.
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Figure 9. SEM images of CS flake before cryo-jet milling at 500X magnification (A)
and resultant CS powder after cryo-jet milling at 1000X (B) and 5000X (C)
magnification.

FTIR
FTIR spectra for CS flake and powder are shown in Figure 10 and reveal
changes in the molecular composition of CS after cryomilling. Specifically, the
amine peak at 3400 cm-1 is lower in the CS powder compared to the CS flake,
which correlates with the conductometric titration data and indicates loss of
amine groups (is this the best way to state what the peak reduction indicates).
There is no change in the amide I peak at 1640 cm-1, but the CS powder shows
a rightward shift at 1100 cm-1 compared to the CS flake. The significance of this
peak shift is not currently understood.
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Figure 10. FTIR spectra of CS flake and powder showing changes in molecular
composition caused by cryo-jet milling. Blue represents chitosan flake, red
represents chitosan powder. Both flakes and powder were analyzed in the free
amine form.

Plasma Decontamination
Plasma treatment resulted in a sterile CS with endotoxin levels of 1.26
EU/g (ApP) and 2.46 EU/g (LpP). This is a very low level of endotoxins. Most
medical or pharmaceutical grades of CS contain > 100 EU/g, although most are
certified to be < 100 EU/g. Plasma sterilization also resulted in a significant
reduction in viscosity of both flake and powder forms of CS, as shown in Figure
11.
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% Reduced Viscosity Retained

100%
90%

80%
70%

No Plasma

60%

LpP 15 mins

50%

LpP 30 mins

40%

ApP 30 mins

30%
20%
10%
0%

Flake

Powder

Figure 11. Effect of LpP and ApP treatment on CS viscosity. Values are % reduced
viscosity retained after LpP or ApP treatment of CS flakes (left grouping) or powder
(right grouping) with untreated CS serving as the control (i.e. 100%).

Solubility
In the process of making CS hydrogels for the tests described in previous
sections, it was noted that cryomilled CS powder solubilized significantly faster
and better in dilute acids than CS flakes. Thus, milling increased the solubility of
CS. This is again a result of the increased surface area of the milled CS
compared to the raw CS flake.

Conclusion
Cryo-ball and cryo-jet milling are effective methods for producing micronsized CS particles and increasing the surface to volume ratio of CS. Cryo-milling
also increases the hygroscopicity and decreases the %DD, intrinsic viscosity,
and therefore the molecular weight, of CS. Cryo-jet milling produced a 44%
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smaller mean particle size than cryo-ball milling after 30 minutes of milling.
However, in the case of cryo-ball milling, smaller grinding balls may produce
much smaller mean particle sizes, potentially within the range of cryo-jet milling,
but it is unclear whether there would be any advantage to cryo-ball milling over
cryo-jet milling.
Plasma-treated CS was sterile with <2.5 EU/g, but NtNP treatment caused
a significant reduction in CS MW. This effect was greater with micronized CS
powder, which is predicted to be due to the increased surface area of the
powder. Future studies must be aimed at elucidating how different particle sizes
influence biological properties of CS.
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Abstract
Chitosan co-formulated with interleukin-12 (CS+IL-12) has shown
remarkable efficacy treating bladder cancer. Translating this and other CScontaining therapeutics is hampered by difficulty sterilizing CS without altering its
biological properties. We hypothesized that low-pressure nitrogen plasma would
sterilize CS while preserving its in vivo functionality. To test this, we plasma
sterilized CS and characterized physicochemical changes and preservation of in
vivo efficacy of CS+IL-12 in a murine orthotopic bladder cancer model (MB-49
tumors). Plasma treatment produced sterile CS with < 2.50 EU/g and reduced CS
viscosity 36.5% and degree of deacetylation 6.3%, but did not alter atomic
nitrogen content or bioadhesivity. Tumors regressed – and mice survived to 90
days – in 88% (n=16) and 92% (n=12) of C57Bl/6 mice treated with unsterile
CS+IL-12 and plasma-sterilized CS+IL-12, respectively, but only 8% (n=12) and
0% (n=3) of mice treated with saline and CS-alone, respectively. Upon tumor rechallenge, 100% of plasma-sterilized CS+IL-12 (n=11) and 91% of unsterile
CS+IL-12 (n=11) treated mice rejected tumors. Tumors established in 25-50% of
CS+IL-12 pre-treated mice, but 92% of tumor naïve mice (n=64). Thus, nitrogen
plasma sterilizes CS while preserving its biologic functionality. Plasma-sterilized
CS will enable human trials to test CS-containing therapeutics including CS+IL12 for bladder cancer and other malignancies.

Keywords: chitosan, bladder cancer, interleukin-12 (IL-12), plasma sterilization,
non-thermal nitrogen plasma (NtNP), immunotherapy, cryo-jet milling
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Abbreviations: CS – chitosan; NtNP – non-thermal nitrogen plasma; LpP – lowpressure plasma; IL-12 – interleukin-12; DD – degree of deacetylation; psCS+IL12 – plasma-sterilized CS+IL-12; usCS+IL-12 – unsterile CS+IL-12
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Introduction
Chitosan (CS) is the deacetylated derivative of chitin, a ubiquitous
biopolymer, and has long been recognized as a promising biomedical material
due to its biocompatibility, biodegradability, hemostatic effectiveness, and antimicrobial properties. (Domb, 2011; Kumirska, 2011) Potential medical
applications for CS are extensive and include gene and drug delivery. One
particularly promising drug delivery application for CS involves local delivery of
cytokines for treating solid tumor cancers. (Heffernan, 2011; Yang, 2013) For
example, recent studies have shown that immune responses generated by local
delivery of interleukin-12 (IL-12), a potent antitumor cytokine that generates
significant toxicity when administered systemically, are robust and durable.
(Zaharoff, 2010; Zaharoff, 2009; Smith, 2015; Vo, 2014; Xu, 2012)
IL-12 has been thought to be a highly promising cancer
immunotherapeutic agent since the early 1990s, just a couple of years after its
discovery in 1989. (Lieberman, 1991; Kobayashi, 1989) Recently, IL-12 was
even ranked third among agents with high potential for use in treating cancer by
the National Cancer Institute (NCI) based on extensive input from academia,
industry, the US Food and Drug Administration (FDA), and the NCI. (Cheever,
2008) However, translating IL-12 to clinical usefulness has been hampered by
toxicities associated with systemic administration that prevents sufficient dosages
from being achieved. (Atkins, 1997; Cohen, 1995; Gollob, 2000; Gollob, 2003;
Hurteau, 2001; Lenzi, 2007; Lenzi, 2002; Motzer, 2001; Robertson, 1999; Weiss,
2003; Younes, 2004) This issue has spurred interest in delivery systems for IL-12
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that can localize IL-12 to the site of interest while also increasing the
concentration and duration at the site of action.
CS has emerged as a leading drug delivery candidate for IL-12 based on
recent studies showing that coformulation of IL-12 with CS (CS+IL-12)
significantly enhances IL-12 efficacy in treating murine bladder, breast,
colorectal, ovarian, and pancreatic tumors. (Zaharoff, 2009; Vo, 2014; Smith,
2015; Yang, 2013; Zaharoff, 2010) In the case of murine orthotopic bladder
tumors, CS+IL-12 resulted in an 88-100% survival rate compared to a 37.5%
survival rate with IL-12 treatment alone and 0% survival rate with BCG, the
current standard treatment for non-muscle invasive bladder tumors. Despite
these outstanding results, which were generated with unsterilized CS containing
endotoxin levels that exceed the levels required for parenteral uses in humans,
CS+IL-12 has yet to be tested in human clinical studies due to issues with
obtaining sterile CS with sufficiently low endotoxin levels and intact biologic
functionality. Standard sterilization techniques like dry/wet heat (i.e. autoclave),
γ-irradiation, electron beam irradiation, and ethylene oxide gas alter the physical
properties of CS such that its functional efficacy is significantly attenuated.
(Franca, 2013; Lim, 1998; Lim, 1999; Marreco, 2004; Rao, 1995; Rosiak, 1992;
San Juan, 2012)
As a precursor to clinical studies testing the safety and efficacy of CS+IL12 in humans, the present study sought to generate a sterile CS that would meet
FDA requirements for use in humans while preserving the biologic functionality of
CS. A novel sterilization technique, non-thermal nitrogen plasma (NtNP), was
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employed as a terminal sterilization method for CS in this study. Plasma,
considered the fourth state of matter after solids, liquids, and gas, consists of an
ionized gas that has emergent properties the gas alone does not. For example,
plasmas are conductive, conductive, and quasi-neutral. Quasi-neutrality means
there are pockets of positive charges and negative charges, but the overall
charge of the plasma is neutral. (Cornelius, 2007; Laroussi, 2005; Moisan, 2001)
We hypothesized that NtNP would adequately sterilize and depyrogenate
CS for parenteral use, increase the nitrogen content of CS thereby increasing its
bioadhesivity, and preserve the biologic functionality of CS. This hypothesis was
tested in an orthotopic murine bladder cancer model. By employing this model,
the study would not only provide insight into the biologic activity of NtNP
sterilized CS, but also an independent replication and expansion of previous preclinical mouse studies of CS+IL-12 for bladder cancer therapy. (Zaharoff, 2009)

Materials and Methods
All reagents were obtained from Sigma-Aldrich unless stated otherwise.

Chitosan
Raw CS flake, with individual flakes ranging in diameter from ~1-15 mm,
was obtained from Scion Biomedical, Inc. After filtering out particles > 8mm in
diameter, the CS flakes were milled into a powder with a cryo-jet mill (MicronMaster Jet Pulverization System, The Jet Pulverization Co., Moorestown, NJ,
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USA). CS was micronized to increase surface to volume ratio – since NtNP is a
surface treatment – and to enhance solubility and in vivo efficacy.

Plasma Decontamination
NtNP treatment was performed with a low-pressure plasma (LpP) system
(IoN40 Gas Plasma System, PVA-TePla America, Inc., Corona, CA, USA).
Treatment times and parameters required to achieve a 6-log reduction in
bacterial spores – considered a sterility dose – with the chosen NtNP system
were determined by treating bacterial indicator (BI) spore strips containing 3.12 X
106 G. stearothermophilus spores and 5.5 x 106 B. atrophaeus spores
(VERIFY™ Dual Species BI, Steris Corporation, Mentor, OH, USA) with NtNP.
The power input for the plasma system was maintained at 500 watts, pressure at
300 mTorr, and gas flow rate at 0.5 L/min. After NtNP treatment, the paper spore
strips were dispersed in sterile water to release the spores from the paper and
the spores were subsequently cultured in tryptic soy agar for 48 and 72 hours at
37°C and 58°C, respectively, to allow growth for each of the 2 spore types.
Prior to NtNP treatment, the micronized CS powder was packaged in
standard sterilization pouches and treated with an overkill dose (2X sterility dose)
of NtNP. CS sterility was confirmed by culturing BIs co-treated with the CS as
described above and diluting the NtNP treated CS powder 1:100 with pyrogenfree water, to overcome the anti-microbial properties of CS, and subsequently
culturing it in tryptic soy agar at 37°C for 72 hours.
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Endotoxin levels were quantitated by incubating CS powder in a 40X (w/v)
volume of pyrogen-free water for 2 hours at 37°C, filtering the extract through a
0.22 μm mixed cellulose esters filter to remove any residual CS that can cause
false positives, and testing the extract for endotoxins using a handheld Limulus
amebocyte lysate (LAL) assay system (Endosafe-PTS device, Charles River,
Inc., Charleston, SC, USA) and FDA-certified 0.5-0.005 EU/mL PTS cartridges. A
recent multi-center trial showed the PTS device is effective in measuring
endotoxin concentrations in medical devices and pharmaceuticals. (Gee, 2008)
Note that endotoxins are measured in endotoxin units (EU), which is a unit
of biological activity based on a reference endotoxin standard. This allows for
standardization of the biologic significance of endotoxin quantities based on
concentration (pg/mL) because different endotoxins elicit varying degrees of
immune responses. (Adner, 1991) The LAL assay is the current gold standard for
quantitating endotoxins and we deviated slightly from the US Pharmacopaeial
and FDA recommendations on LAL endotoxin testing by extracting the
endotoxins at 37°C, instead of room temperature, based on previous
experiments in our laboratory that have shown significantly higher extraction
rates at 37°C (data not shown). (US Dept. of Health and Human Services, 2012)

Viscosity
It is important to characterize the viscosity of CS for any pharmaceutical
applications since viscosity is a surrogate measure of molecular weight (MW)
and the biological properties of CS are dependent on its MW. (Dodane, 1998;
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Kumirska, 2011; Kumirska, 2011) Rinaudo and colleagues have described
methods for viscometric determinations of CS in detail and those studies formed
the basis for the techniques used here. (Brugnerotto, 2001; Rinaudo, 1993)
Briefly, the intrinsic viscosity of the native and NtNP-sterilized CS powder was
determined by measuring efflux times of CS solutions using a 2-10 centistoke
glass capillary ASTM 1 Ubbelohde Viscometer (Fisher Scientific, Pittsburgh, PA,
USA). For these measurements, CS was dissolved in 0.3 M acetic acid and 0.2
M sodium acetate (0.3 M AcOH/0.2 M NaOAc) for final concentrations of 1, 1.5,
and 2 mg/mL (0.1%, 0.15%, and 0.2%). Efflux times were measured for each of
the 3 concentrations and intrinsic viscosity was determined using the Huggins
plot, in which the reduced viscosities for the 3 concentrations are extrapolated to
zero concentration. Reduced viscosity for each concentration was calculated by
the following equation:
𝑡

Reduced Viscosity nred=(𝑡 𝑐𝑠 − 1) ÷ 𝑐
𝑠𝑜𝑙

(1)

where tcs represents efflux time for CS, tsol represents efflux time for the solvent
(0.3 M AcOH/0.2 M NaOAc), and c represents CS concentration in g/mL.

Surface Atomic Concentrations
Because previous studies have shown changes in the elemental
composition of plasma-treated CS films after plasma treatment, which may have
an effect on the bioadhesivity of CS, the elemental composition of NtNP-treated
and native CS powder was analyzed via X-ray Photoelectron Spectroscopy
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(XPS). (Ogino, 2008; de Oliveira Cardoso Macedo, 2013) We hypothesized that
NtNP may add nitrogen groups to the CS. Since the amine group is the source of
CS’s cationic charge, adding nitrogen may increase the positive charge of CS
and resultantly, its bioadhesivity. XPS characterization was performed using a
Kratos AXIS ULTRADLD XPS system equipped with an Al Kα monochromated Xray source and a 165-mm radius electron energy hemispherical analyzer.
Vacuum pressure was kept below 3 x 10-9 torr during acquisition. CS powder was
affixed to a piece of tape during the XPS scanning process to prevent movement
of the particles in the acquisition chamber.

Degree of Deacetylation
As with viscosity/MW, degree of deacetylation (DD) must be characterized
for any biomedical application of CS since DD has a significant impact on the
biological properties of CS. (Kumirska, 2011; Dodane, 1998) DD determinations
were carried out by conductometric titration following the protocol reported by
Raymond and colleagues. (Raymond, 1993) Briefly, dried CS sample of known
mass (about 0.100 g) was dissolved in 10 mL of 0.1 N hydrochloric acid (HCl)
and 90 mL of distilled water. The CS solution was subsequently titrated with a
standard sodium hydroxide (NaOH) solution using a 10 mL buret while the
conductivity of the solution was monitored as a function of the volume of NaOH
added with an Orion Benchtop Conductivity Meter (Model 162) equipped with an
Orion Conductivity Cell (Model 013030). The temperature of the solution was
kept constant (30°C) during the titration using a water bath since the conductivity
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is a function of temperature. There are two deflection points in the
conductometric titration curve, the first corresponding to the neutralization of
excess H+ ions of the strong acid, HCl, and the second corresponding to the
point at which the weak acid, the ammonium salt in CS, has been completely
neutralized. The range between the 2 deflection points corresponds to the
neutralization of the protonated amine groups of CS. Since the number of moles
of NaOH used between the 2 deflection points equals the number of moles of
amine groups of the CS sample, the DD was calculated by the following
equation:

%DD =

(𝑣2−𝑣1) × 𝑀𝑁𝑎𝑂𝐻 (

𝑚𝑜𝑙
161.16𝑔
)×
𝐿
𝑚𝑜𝑙

𝑀𝑎𝑠𝑠 𝑜𝑓 𝑐ℎ𝑖𝑡𝑜𝑠𝑎𝑛 𝑠𝑎𝑚𝑝𝑙𝑒 (𝑔)

× 100

(2)

where (v2-v1) is the difference in volume in liters between the two deflection
points, MNaOH is the molarity (mol/L) of standard NaOH solution, and 161.16 is
the molar mass of CS. Titrations were performed in duplicate on each sample.

Bioadhesivity
One of the mechanisms by which CS is thought to enhance IL-12 efficacy
is through adhesion to tissues based on the cationic charge of CS and the
anionic charge of tissues. (Sinha, 2004; Zaharoff, 2007; Yang, 2013; Zaharoff,
2009) Thus, the effect of NtNP sterilization on bioadhesion of CS was assessed.
The technique we employed for measuring bioadhesion was adapted from a
study by Hurler and Skalko-Basnet. (Hurler, 2012) For this technique, CS powder
was first solubilized with 1% acetic acid overnight at 4°C to form 1% CS
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solutions. Fresh pig bladders were obtained on the day of testing and kept on ice
until measurements. Immediately prior to testing, bladder samples were rinsed
with 70% ethanol and allowed to dry for 60 seconds at room temperature. For
testing, a polystyrene culture plate (Fisher Scientific, Inc., Pittsburgh, PA, USA)
was centered on a standard laboratory balance with a 0.001-100g range (Fisher
Scientific, Inc.) and a 50 μL volume of 1% CS acetate solution was dispensed
into the center of the plate and the weight recorded. A piece of pig bladder that
fully covered the CS solution was placed over the CS and a 200g weight applied
for 30 seconds. After 30 seconds, the weight was removed followed by the
bladder. Care was taken to ensure the bladder was removed using the same
technique for each sample. The weight on the balance was again recorded. The
% loss in mass of the CS solution after applying and removing the bladder was
considered a surrogate measure for bioadhesivity. Each solution was tested
twice, with a fresh piece of pig bladder for each test, and 3 samples from each
treatment group were tested.

Chitosan+IL-12 Co-formulation
NtNP-sterilized CS powder was aseptically transferred to sterile 50 mL
polypropylene tubes (Fisher Scientific, Inc.) and solubilized with sterile-filtered
1.25% lactic acid (Sigma Aldrich, St. Louis, MO, USA) in 1X phosphate buffered
saline (PBS) (Thermo Fisher Scientific, Inc., Waltham, MA, USA) for a final CS
concentration of 1.25%. Immediately prior to use, the CS lactate solution was
combined with recombinant murine IL-12 (rMuIL-12) (Peprotech, Inc., Rocky Hill,
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NJ, USA) that had previously been reconstituted with 1X PBS to achieve final
concentrations of 20 μg/mL rMuIL-12, 1% CS, and 1% lactic acid.

Cell Culture
MB-49lucSH+ cells, an aggressive murine transitional cell carcinoma (TCC)
tumor line that shares many characteristics of human bladder cancer including
cell surface markers, sensitivity to apoptosis, and immunologic profile, were
obtained by material transfer agreement from the National Cancer Institute
(generous gift of Jeffrey Schlom and Jack Griener). (Loskog, 2005; O'Donnell,
2004; Loskog, 2004) The MB-49lucSH+ cells had been previously stably
transfected with a plasmid encoding a synthetic CpG-free firefly luciferase zeocin
resistance fusion gene (pSELECT-zeo-LucSh; InvivoGen, Inc., San Diego, CA,
USA). MB-49lucSH+ cells were maintained in Dulbecco’s Modified Eagle Medium
supplemented with GlutaMAX, 10% fetal bovine serum, 1%
penicillin/streptomycin, and 200 μg/mL zeocin (InVivoGen, Inc.). Zeocin acted as
the selection agent for the plasmid-expressing cells. All cell culture reagents
were obtained from Thermo Fisher Scientific, Inc. unless otherwise specified.
On the day of cell injections, MB-49lucSH+ cells were prepared by
trypsinizing the cells, re-suspending in culture media for a final concentration of
1.5 x 106 cells/mL, and placing 1.5 mL aliquots in 2 mL sterile microcentrifuge
tubes until intravesical injection.

65

Tumor Cell Injections and Confirmation
Female C57Bl/6 and BALB/c mice were obtained from The Jackson
Laboratory (Sacramento, CA, USA) after obtaining approval from the Loma Linda
University Institutional Care and Use Committee and used at 7-10 weeks of age.
Mice were cared for in compliance with The Guide for Care and Use of
Laboratory Animals (National Research Council). These two mouse strains were
chosen for this study to elucidate the impact of different immune phenotypes on
the efficacy of CS+IL-12. Specifically, BALB/c mice have a Th2 polarized
response to invading pathogens with low levels of IL-12 production whereas
C57Bl/6 have a predominantly Th1 polarization. (Lichtman, 2013; Schulte, 2008;
Mills, 2000; Chen, 2005) However, this long-held belief has come under scrutiny
recently with a study showing that BALB/c mice have a Th1 polarized response
induced by BCG vaccination. (Garcia-Pelayo, 2015) We hypothesized that
BALB/c mice might be less responsive to IL-12 therapy than C57Bl/6 mice since
IL-12 stimulates a Th1 response.
For establishment of orthotopic bladder tumors, methods were adapted
from previous studies. (Dobek, 2011; Kasman, 2013) Mice were anesthetized
with 2-3% isoflurane, placed supine, and 24 G ¾ inch SURFLO Teflon catheters
(Terumo Medical Corporation, Somerset, NJ, USA), coated with water-based
lubricating jelly and introducer needles removed, were inserted into the urethra
while the vulva was gently pulled antero-inferiorly at 45 degrees from horizontal
with surgical forceps to straighten the curved murine urethra. After
catheterization, urine was drained into the catheter by applying gentle manual
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pressure to the bladder and suctioning the resultant urine from the catheter tip
with a pipette.
Fifty microliters of 0.1 μg/mL poly-L-lysine (PLL) (molecular weight 70,000150,000; Sigma Aldrich) in sterile water for injection was then injected and held in
place for 10 minutes by drawing 80 μL of PLL solution into the SURFLOW
introducer needle with a 1 mL syringe, inserting the needing into the catheter
until slight resistance was met, expelling the solution in the introducer needle unit
until the meniscus reached the proximal tip of the needle, and taping the syringe
in place. Care was taken to avoid introducing air into the bladder. After 10
minutes, the PLL solution was suctioned from the bladder, the introducer needle
removed while the catheter was left in place, 80 μL of 1.5 x 10 6 cells/mL MB49lucSH+ cell suspension was drawn into a new introducer needle, and the needle
placed into the catheter as before with 50 μL of the cell suspension (75,000 cells)
subsequently injected into the bladder (30 μL deadspace in the needle) and held
in place for 35 minutes.
Tumor presence was confirmed and monitored over time via
bioluminescent imaging with an IVIS Lumina Series III Pre-clinical In Vivo
Imaging System (Perkin-Elmer, Waltham, MA, USA). For bioluminescent
imaging, 15 mg/kg D-Luciferin potassium salt (Sigma Aldrich) in 1X PBS was
given via intraperitoneal injection 15 minutes prior to imaging. Mice were imaged
for 1 minute with large binning and medium f/stop.
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Intravesical Treatments
Intravesical treatments with PBS, CS hydrogel alone (CS-only), plasmasterilized CS+IL-12 (psCS+IL-12), or unsterile CS+IL-12 (usCS+IL-12) were
administered to tumor bearing mice using the same technique described above
for the PLL and MB-49lucSH+ cell injections, with 35 minute dwell times. All CScontaining treatments contained 1% CS lactate and all IL-12 containing
treatments contained 20 μg/mL IL-12 for a total of 1 μg rMuIL-12 per mouse per
treatment. Treatments were administered every 3-5 days with a total of 4
treatments per animal.
To monitor for treatment-related toxicity, a group of tumor naïve mice
received CS+IL-12 treatments, but were never challenged with tumors.

Tumor Re-challenge
Mice that became tumor-negative on bioluminescent imaging for more
than 3 consecutive weeks after the conclusion of the treatment regimen were rechallenged with tumor cells 8 weeks after the initial tumor cell instillation, which
was 5 weeks after the 4th treatment was administered. The MB-49lucSH+ cell
instillations were again performed as described above. At the time of rechallenge, tumor naïve mice were also challenged with tumor cells to ensure
appropriate percentages of tumor establishment were achieved.
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CS+IL-12 Vaccination of Mice
Groups of tumor naïve mice received psCS+IL-12 (n=4) or usCS+IL-12
(n=4) treatments prior to tumor challenge. The treatments were administered as
described above for tumor-bearing mice. Tumor instillation was performed 5
weeks after the final treatment was given.

Euthanasia
Mice were sacrificed via cervical dislocation after inducing anesthesia with
3% isoflurane.

Statistical Analyses
Non-parametric data (tumor establishment, tumor regression) were
analyzed by Pearson’s chi-squared test with p<0.05 considered significant.
Additionally, survival data were analyzed by the log-rank test with p<0.05
considered significant. Parametric data were analyzed by two-tailed student’s ttest (bioadhesion) with p<0.05 considered significant.

Results
NtNP Effectively Sterilized CS
Cryo-jet milled CS powder had an average particle diameter of 16.05 μm,
a significant increase in surface to volume ratio compared to the raw CS flakes. It
was also observed that the CS powder solubilized faster with fewer insolubles
than CS flake. NtNP achieved a 6-log reduction in spores after 15 minutes
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(Figure 12). Since it is common practice to utilize an overkill dose for sterilization
of medical devices and pharmaceuticals, CS powder was treated for 30 minutes
with NtNP, which resulted in a sterile CS preparation. Endotoxin levels in the CS
powder after NtNP sterilization were 2.47 EU/g. After solubilizing CS with lactic
acid making a 1% CS solution, endotoxin levels (0.02 EU/mL) were far below the
required 0.5 EU/mL for internal use of CS.

Figure 12. Log reductions in spore viability from BIs with increasing exposure to
non-thermal N2 plasma treatment. A sterilization dose represents a 6-log reduction
in spore viability. Data points represent log reductions in mean colony forming
units; n=3 each time point.
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NtNP Reduced CS Viscosity
Viscometric measurements showed that NtNP sterilization decreased the
intrinsic viscosity of CS by 36.5% (Figure 13). The change in viscosity was also
observed in the time it took for the catheters to fill with psCS+IL-12 versus
usCS+IL-12 during animal treatments.
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Figure 13. Intrinsic viscosity of micronized CS powder before and after NtNP
sterilization. Values are the y-intercept of reduced viscosities for 3 concentrations
of CS (n=3 per concentration, measured in duplicate) when extrapolated to zero
concentration on Huggins Plot.

NtNP Altered DD, Not Surface Atomic Concentrations
According to the conductometric titrations, CS DD was reduced from
73.75% to 69.11% with NtNP sterilization. XPS measurements revealed that
there was no change in the nitrogen content of the CS powder. There was a 1%
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decrease in oxygen content and 1% increase in carbon content, which might be
explained by residual air in the plasma chamber or absorbed on the CS surface.

CS Bioadhesion Unchanged with NtNP Sterilization
The bioadhesion studies showed that there was no significant change,
whether positive or negative, in the bioadhesivity of CS after NtNP sterilization
(Fig. 14). These data correlate with the XPS data as we had hypothesized that
NtNP treatment would increase the bioadhesion of CS through increasing the
nitrogen content.
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Figure 14. Bioadhesivity of native and NtNP sterilized CS. Values are mean ±
standard error of the mean (SEM); n=3 each group, measured in duplicate.
Statistical significance (p<0.05) was not reached.
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Orthotopic Tumors Established in Most Animals
Figure 15 shows success rates in tumor establishment in both BALB/c and
C57Bl/6 mouse strains. The tumor establishment rates we achieved with
injections of 75,000 cells in C57Bl/6 mice were in between rates achieved by
Loskog et al in which both higher and lower numbers of cells (60,000 and
100,000) were used for tumor instillation. (Loskog, 2005) Loskog achieved a
100% tumor establishment rate when injecting 100,000 cells. Taken together,
these data indicate 100,000 cells should be injected for establishing orthotopic
MB-49 tumors in C57Bl/6 mice.
Although tumor establishment rates were not significantly different
between strains, tumors spontaneously regressed in all but one of the BALB/c
mice in all treatment groups, including the control PBS-treated group (data not
shown). Interestingly, the sole BALB/c mouse that retained its tumor developed a
large abdominal tumor secondary to bladder puncture that inadvertently occurred
during MB-49 cell instillation. The spontaneous tumor regression observed in
BALB/c mice is likely explained by the fact that the MB-49 cell line is derived from
C57Bl/6 mice, which have an MHC H2b haplotype whereas BALB/c mice have an
H2d haplotype. This MHC mismatch appears to lead to transplant rejection in the
BALB/c mice since the rejections generally occurred in all groups, including the
PBS control, within 10-14 days, a timeline similar for transplant rejection (7-10
days). (Janeway, 2001) On the other hand, the MB-49 cell line is derived from
male mice and used in female mice to enable urethral catheterization, yet the HY
antigen appears to be innocuous. (Loskog, 2005) We had hypothesized that the
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immunosuppressive nature of the tumor microenvironment might prevent

Percent Tumor +/-

transplant rejection in BALB/c mice based on the MHC mismatch.
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Figure 15. Success rates of orthotopic tumor establishment in BALB/c and C57Bl/6
mice. Values represent percent of mice that were tumor positive (lower, dotted
bars) and tumor negative (upper, striped bars) in each strain after tumor cell
instillation. Difference was not statistically significant at p<0.05 by Pearson’s chisquared test.

CS+IL-12 Eliminated Tumors in Most C57 Mice
In C57Bl/6 mice, the CS+IL-12 treatment groups showed outstanding
response rates to treatment with 11 of 12 usCS+IL-12 treated mice and 14 of 16
psCS+IL-12 treated mice becoming tumor negative within 60 days of the start of
therapy (Fig. 16). It was observed that we had technical difficulties with treatment
administration in all 3 mice that failed to respond to therapy. These issues ranged
from difficulty catheterizing the urethral to treatment leakage around the catheter
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due to an abnormally large urethra. Tumors regressed in only 1 of 12 PBS
treated mice (Fig. 16) and 0 of 3 CS-alone treated mice. Thus, MB-49 tumors
persist in the absence of treatment and CS-alone completely lacks anti-tumor
properties.
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Figure 16. Longitudinal tumor regression after intravesical treatment. Data points
represent percentage of mice imaging positive for tumors with bioluminescent
imaging. Both psCS+IL-12 (n=16; square data points) and usCS+IL-12 (n=12;
diamond data points) treatment groups had significantly less tumor positive mice
than the saline control group (n=12; triangle data points) from 30-90 days
(p<0.001). There was no significant difference between psCS+IL-12 and usCS+IL12 at any time point. Statistical significance at or below p<0.05 calculated by
Pearson’s chi-squared test.

Over 75% of the C57Bl/6 mice treated with CS+IL-12 were tumor negative
within 30 days of administering the first treatment. In fact, approximately 50% of
the mice were tumor negative after only 2 treatments. As such, Figure 17 shows
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representative bioluminescent scans of tumors in 1 mouse from each treatment
group over the course of treatment.

Luminescence
1st Tx
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Figure 17. Anti-tumor activity of intravesical treatments. Images show longitudinal
bioluminescent tracking of tumors in C57Bl/6 mice bearing orthotopic MB-49lucSH+
tumors during treatment with saline (upper left image panel), psCS+IL-12 (upper
right image panel), and usCS+IL-12 (lower image panel). Imaging took place on
day of intravesical instillation of treatments. Post-treatment imaging took place 4
days after receiving treatment 4. Tx – treatment; usCS+IL-12 – unsterilized CS+IL12; psCS+IL-12 – plasma sterilized CS+IL-12.

Survival Unchanged by NtNP Sterilization
A Kaplan Meier survival curve is presented in Figure 18 showing percent
survival out to 90 days after tumor instillation. There was no significant difference
in survival between the CS+IL-12 treatment groups (p>0.05), but a very
significant difference compared to the saline group (p<0.001). Additionally, the
survival rates for both psCS+IL-12 (88% survival) and usCSIL-12 (92% survival)
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match the results found previously by Zaharoff and colleagues (88-100%
survival). (Zaharoff, 2009) However, the median survival time for saline treated
animals was significantly longer (p<0.01) in our study (55 days) than in the
Zaharoff study (18 days). This difference is likely explained by the subjective
nature of determining when mice must be sacrificed due to tumor-related
morbidity or differences in location or severity of orthotopic tumor establishment.
No adverse events or toxicity were noted as a result of CS+IL-12 therapy.

100.00%

Percent Survival

80.00%
60.00%

psCS+IL-12
40.00%

usCS+IL-12

20.00%

Saline

0.00%
0
50
100
Time After Tumor Instillation (days)

Figure 18. Survival after tumor instillation. C57Bl/6 mice were treated with
psCS+IL-12 (n=16), usCS+IL-12 (n=12), or phosphate buffered saline (n=12)
starting 7 days after tumor instillation. Survival time was significantly longer for
both CS+IL-12 treatment groups compared to saline control (p<0.001; log-rank),
but there was no significant difference between CS+IL-12 groups.

Re-challenge After Tumor Regression
A major problem with superficial bladder cancer is high recurrence rates.
In fact, bladder cancer is the most expensive cancer to treat due to the high
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recurrence rates. (Van Der Heijden, 2009; van Rhijn, 2009) Approximately 2050% of patients with bladder cancer who are treated successfully with the current
standard of care (transuretheral resection followed by intravesical BCG) will have
recurrent tumors within 5 years. (Herr, 2003; Kamel, 2009; Lamm, 2000;
Malmstrom, 1999 These recurrent tumors are frequently resistant to BCG. Thus,
we re-challenged the “cured” mice with tumor cells 8 weeks after initial MB-49
cell instillation. We found that 100% of psCS+IL-12 treated and 91% of usCS+IL12 treated mice rejected the tumors outright (Table 2). Tumors established in
100% of the tumor naïve mice. The one treated mouse that imaged tumor
positive had received usCS+IL-12 and survived 30 days after tumor re-challenge
before sacrifice with evidence of a bladder tumor. Thus, there appears to be a
strong anti-tumor immunity generated by CS+IL-12 in the gross majority of
animals.

Table 2. Tumor establishment in tumor-exposed and tumor naïve mice treated
with plasma sterilized and unsterilized CS+IL-12.
# of Mice Tumor
Positive

# of Mice Tumor
Negative

Total # of Mice

Tumor Naïve

6

0

6

psCS+IL-12

0

11

11

usCS+IL-12

1

10

11

psCS+IL-12vax

1

3

4

usCS+IL-12vax

2

2

4
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Vaccination
Pre-treated, or “vaccinated,” mice were given 4 treatments of CS+IL-12
while tumor naïve and then were challenged with MB-49 cells 5 weeks after their
4th treatment. This treatment regimen resulted in 25% of mice developing tumors
after psCS+IL-12 pre-treatment (psCS+IL-12vax) and 50% of mice developing
tumors after usCS+IL-12 pretreatment (usCS+IL-12vax) (Table 2). These data
and the fact that the tumor establishment rate for CS+IL-12-naïve mice was
92.2% overall suggest that administration of CS+IL-12, even prior to tumor
instillation, results in tumor protection, though the effect is profoundly improved
with treatment after tumor establishment.

Discussion
Our results show that NtNP treatment effectively sterilized and
depyrogenated CS while preserving its efficacy as an excipient for immune
molecules like IL-12. This indicates that potential contaminants present in
unsterilized CS do not enhance the efficacy of CS+IL-12 treatment by, for
example, bolstering the immune response elicited by CS+IL-12. This is an
important finding since previous studies have found that many of the biologic
properties of CS, especially those related to the immune response it triggers, are
influenced by contaminants in CS such as endotoxins. (Lieder, 2013; Nolte,
2014)
Previous studies have also shown that MW influences the bioadhesion of
polymers, including CS, with bioadhesivity decreasing as MW decreases.
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(Honary, 2009; Roy, 2010) However, we did not find a reduction in bioadhesivity
of CS after NtNP sterilization despite a 36.5% reduction in intrinsic viscosity,
which is a surrogate measure of MW. This phenomenon might be explained by
previous studies demonstrating that bioadhesivity usually becomes significantly
reduced once MW falls below 100 kDa. (Roy, 2010) The NtNP-treated CS
produced in this study still had a MW >250 kDa, based on the Mark-Houwink
equation and K and α values of 0.074 and 0.80, respectively. (Brugnerotto, 2001)
Since the cationic charge of CS is responsible for its bioadhesive
properties and the NtNP sterilization did not significantly alter bioadhesivity, it is
reasonable to conclude that the cationic charge of CS was also not changed.
This suggests that CS exerts its effect on the delivery of IL-12 in the bladder
through its cationic charge. The specific mechanism is likely a combination of
prolonging residence time of IL-12 on the surface of the bladder transitional
epithelium through binding to negatively charged sialic acid residues,
glycosaminoglycans, mucin, and proteoglycans on the cell surface and
enhancing penetration of IL-12 through the bladder wall by increasing the
permeability of epithelial barriers. (Mi, 2002; Sinha, 2004; Illum, 1994) This
conclusion is supported by a study that has effectively demonstrated the
dependence of CS’s cationic charge on enhancing epithelial permeability through
redistribution of cytoskeletal F-actin and zonula occludens-1 (ZO-1). (Schipper,
1997) The cationic charge not only mediates adhesion of CS to tissues and
penetration of epithelial barriers, but is also responsible for virtually every other
advantageous biomedical characteristic CS possesses including its
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biocompatibility, biodegradability, anti-microbial, wound healing, and analgesic
properties. (Domb, 2011) Thus, preservation of the cationic charge of CS after
sterilization is paramount.
Survival rates of CS+IL-12 treated C57Bl/6 mice, even when sterilized with
NtNP, in the present study mirrored the results found by Zaharoff et al at the NCI
in which CS+IL-12 dramatically prolonged the survival rates of MB-49 tumorbearing mice and eliminated tumors in at least 88% of the mice. (Zaharoff, 2009)
Thus, we have independently confirmed the exceptional anti-tumor properties of
CS+IL-12 in treating orthotopic murine bladder tumors and extended the results
to a CS that complies with sterility and pyrogen levels required for parenteral use
of CS.
The very low number of animals that established tumors upon rechallenge also confirmed the findings by Zaharoff et al that durable immunity is
achieved with CS+IL-12 therapy. Moreover, the vaccination effect we observed
suggests that immunity can be generated even in the absence of tumor. Thus,
prophylactic treatment, or vaccination, with CS+IL-12 may be effective in
preventing the development of bladder cancer. Such a vaccination could be
useful for individuals at high risk of developing bladder cancer like smokers, the
genetically predisposed, and workers with certain occupational exposure
hazards. (Kirkali, 2005; Pasin, 2008)
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Perspective and Significance
Bladder cancer is a significant burden both in the US and abroad. It is well
established as the 5th most common cancer in the US with over 70,000 new
cases diagnosed each year. (Jemal, 2010; Siegel, 2012; Siegel, 2013; Siegel,
2011) As the most costly cancer to treat due to high recurrence rates, new
approaches for bladder cancer therapy are needed. (Van Der Heijden, 2009; van
Rhijn, 2009) Significantly, the current standard of care for treating bladder
cancer, which consists of transurethral resection followed by intravesical BCG
therapy, has been such for over 30 years despite major advances in the
treatment of other urologic malignancies. (Askeland, 2012) A major issue with
BCG that is currently plaguing urologists and bladder cancer patients is an
ongoing shortage of intravesical BCG. According to the FDA CBER-Regulated
Products: Current Shortages webpage, this shortage has been ongoing since
May 2012. This shortage has a real impact on the treatment of bladder cancer
patients (personal communication).
Taken together, our results presented herein and those previously
reported by other laboratories suggest that human trials testing CS+IL-12 for the
treatment of non-muscle invasive bladder cancer should commence with NtNPsterilized CS+IL-12. No toxicity or side effects of the CS+IL-12 were noted in the
current study or previous studies. There is also extensive animal and human data
suggesting that CS will be a safe pharmaceutical excipient in humans. (Baldrick,
2010) Moreover, a phase I human clinical trial showed that intravesical IL-12
therapy is safe in humans. (Weiss, 2003) In fact, that trial failed to establish the
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max tolerated dose of intravesical IL-12 in humans despite a dose-escalation
design. Beyond bladder cancer, we believe human trials for treating other tumors
of epithelial origin, including breast, colorectal, ovarian, and pancreatic tumors,
with CS+IL-12 are indicated based on promising results in mice. (Vo, 2014;
Yang, 2013; Zaharoff, 2010; Hurteau, 2001; Lenzi, 2002) Moreover, CS should
be considered as a more general drug delivery vehicle for not only other
cytokines and peptides, but also other chemotherapeutic agents. (Kato, 2005)
Development of a sterile, depyrogenated CS that is functional and safe for
parenteral use will have indications beyond cancer therapy. Numerous studies
have shown that CS-containing vaccines produce superior immune responses to
those containing traditional adjuvants like aluminum hydroxide. (Zaharoff, 2007;
Chua, 2015; Li, 2015; Powell, 2015) CS also enables novel routes of delivery for
vaccines, including nasal and oral, that are non-invasive and convenient
compared to the traditional injection-based vaccines. (Xia, 2015)

Conclusions
NtNP treatment produced CS that was sterile with endotoxin levels that
are below the level required for parenteral indications. Biologic functionality of CS
is also preserved with NtNP sterilization as demonstrated by therapeutic efficacy
of psCS+IL-12 in treating orthotopic murine bladder tumors equivalent to
usCS+IL-12. Human trials testing the safety and efficacy of NtNP sterilized
CS+IL-12 are indicated and treating individuals at high risk of developing bladder
cancer with a CS+IL-12 “vaccine” should be considered.
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Abstract
Introduction: The U.S. military has had success with chitosan-based hemostatic
agents to control trauma-induced hemorrhages. Despite the positive reviews,
additional physical forms of chitosan may enhance its hemostatic efficacy.
Additionally, standard sterilization techniques may negatively affect the
hemostatic efficacy of chitosan. We studied the effects of a chitosan-based
hemostatic pad, the Clo-Sur P.A.D., on severe femoral vessel bleeding in a rat
model. The effects of different sterilization techniques on the bioadhesivity,
surface atomic concentrations, and hemostatic efficacy of the P.A.D. were also
evaluated.

Methods: Hemostatic efficacy, bioadhesivity, and surface atomic concentrations
of the P.A.D. were evaluated in its unsterilized form, after sterilization with
standard e-beam treatment, and after sterilization with one of three types of nonthermal nitrogen plasma, nitrogen gas, air, or nitrous oxide plasma. After
standardized puncture of the femoral artery or transection of the femoral vessels,
rats were treated with either a chitosan P.A.D. or gauze pad.

Results: The Clo-Sur P.A.D., regardless of sterilization technique, stopped
arterial and mixed arterial/venous bleeding in all cases in < 90 seconds with the
time to hemostasis (TTH) significantly less for all P.A.D. treatment groups
(p<0.001; n=4-5/group) compared to gauze-treated controls (n=3). E-beam
sterilized P.A.D.s consistently showed non-significant trends toward increased
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TTH and worse hemostasis scores compared to unsterilized and plasmasterilized P.A.D.s. Treating e-beam sterilized P.A.D.s with N2 plasma reverted the
hemostatic efficacy to levels equivalent to native, unsterilized PADs.

Conclusion: A chitosan-based hemostatic pad successfully controlled severe
bleeding in a rat model with combined e-beam+plasma sterilized P.A.D.s
showing the most promising results. Further studies are warranted.

Keywords: chitosan, plasma sterilization, hemostasis, hemostatic agents, nonthermal nitrogen plasma, rat model

Abbreviations: CS – chitosan; NtNP – non-thermal nitrogen plasma; TTH – Time
to Hemostasis;
ApP – atmospheric pressure plasma; LpP – low-pressure plasma; DD – degree
of deacetylation; DFSD – dry fibrin sealant dressing; RDH – rapid deployment
hemostat; HC – HemCon Bandage
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Introduction
Nearly 10% of the U.S. population (30,888,063 people) experienced nonfatal injuries in 2013, the most recent year for which data are available from the
CDC. An additional 192,945 people suffered fatal injuries in 2013 according to
the CDC making unintentional injury the leading cause of death in the U.S. for
individuals aged 1-44 years and the largest cause of years of potential life lost
before age 65. (WISQARS, 2013) Hemorrhage is the second leading cause of
death after injury, trailing behind only central nervous system (CNS) damage.
(Kauvar, 2006) In the war theater, hemorrhage is the leading cause of death for
combat casualties. (Champion, 2003)
In contrast to CNS injury, many methods are available to reduce or stop
bleeding. There are currently four main hemostatic agents used to control
hemorrhage in the prehospital setting. These four hemostatic agents include the
dry fibrin sealant dressing (DFSD), rapid deployment hemostat (RDH), HemCon
Bandage (HC), and QuickClot. DFSD is a lyophilized polygalactin mesh
containing human fibrinogen, human thrombin, and calcium chloride, RDH is a
lyophilized poly-N-acetyl-glucosamine bandage, HC Bandage is a lyophilized
chitosan pad, and QuikClot is a granular zeolite powder. The only one of these
four hemostatic agents that meet all 7 criteria for the ideal hemostatic dressing
for prehospital use is chitosan. (Pusateri, 2006)
Chitosan (CS) is the deacetylated derivative of chitin, the second most
abundant biopolymer on Earth. CS is derived from crustacean shells, insect
exoskeletons, fungi, and algae and has been studied for its hemostatic properties
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since 1983 when Malette and colleagues showed that blood, even when
defibrinated and heparinized, forms a coagulum when in contact with CS.
(Malette, 1983) Numerous animal and human studies have confirmed in vivo that
the hemostatic efficacy of CS is superior to gauze and at least equivalent to other
advanced hemostatic agents both under normal and anti-coagulant conditions.
(Kind, 1990; Subar, 1997; Brandenberg, 1984; Kourelis, 2012; Klokkevold, 1991;
Klokkevold, 1992; Klokkevold, 1999; Xie, 2008; De Castro, 2012; Rajiv, 2013;
Hattori, 2010; Dailey, 2009; Ahuja, 2006; Huang, 2015; Pusateri, 2003;
Wedmore, 2006) Studies have also shown that topical use and implantation of
CS in mammals does not produce toxicity or tissue reactivity and CS is rapidly
resorbed after implantation. (Xie, 2012; Kean, 2010; Onishi, 1999; Richardson,
1999)
The extensive animal studies on CS culminated in the U.S. Office of the
Surgeon General mandating in September 2005 that every soldier carry a CS
hemostatic dressing (HC Bandage, HemCon Medical Technologies, Portland,
OR). Combat Lifesavers and combat medics were mandated to carry 3 and 5 CS
bandages, respectively. (Cordts, 2008) After 42 of 44 uses of the HemCon
bandage in a combat setting were successful with no adverse effects
documented, a report proposed adding two CS based hemostatic agents, Celox
and ChitoGauze, to the Tactical Combat Casualty Care Guidelines. (Bennett,
2014) The same report describes widespread use of CS-based hemostats by
NATO militaries, emergency medical service (EMS) agencies and law
enforcement agencies in addition to the U.S. military. Although human studies
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and roughly a decade of use have shown that CS dressings are effective
hemostatic agents, there is significant room for improvement. (Pusateri, 2006;
Alam, 2005)
Some of the issues identified with current CS-based hemostatic agents
include issues with batch to batch variability in molecular weight (MW) and
degree of deacetylation (DD) - both of which influence hemostatic efficacy - and
low malleability that prevents easy manipulation to fit deep or jagged wound
surfaces. (De Castro, 2012; Whang, 2005; Ahuja, 2006) Variations in MW and
DD are likely a result of natural variability in the source of CS, which is typically
crustacean shells, and inconsistencies in converting raw chitin extracts from
crustacean shells to CS. (Kumirska, 2011; Kumar, 2004) However, sterilization
methods also play a role since conventional sterilization techniques reduce CS
MW. For example, electron beam sterilization reduced the MW of CS by 56%
and gamma irradiation induced main chain scissions in CS fibers and films that
decreased the MW of CS by 25%. (Dutkiewicz, 1989; Lim, 1998) Additional
issues regarding sterilization of CS via traditional methods include chemical
alterations of CS and residual toxic residues. (Franca, 2013; Lim, 1999; Marreco,
2004; Rao, 1995; Ulański, 1992)
Reduction in the MW of CS reduces its adhesion strength to tissues by
limiting chain flexibility for interpenetration and entanglement of tissue proteins
and mucus. (Whang, 2005) This effect is demonstrated by the failure of low
molecular weight CS to form a firm coagulum when exposed to blood in vitro.
(Lee, 1975) Other factors that affect the bioadhesivity of CS, like DD and degree
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of ionization, also may reduce its hemostatic efficacy since it is postulated that
CS induces hemostasis via red blood cell agglutination and a “velcro-like”
adhesion to tissue surfaces. (Whang, 2005; Dowling, 2011)
The aim of the present study was to improve the hemostatic efficacy of a
topical CS hemostatic agent (Clo-Sur P.A.D.™, Scion Cardio-Vascular, Inc.,
Miami, FL) by using non-thermal nitrogen gas plasma (NtNP), a non-conventional
sterilization method. Though low-temperature plasmas have been shown to
effectively sterilize materials, including wound care bandages, they have not
been used widely in medicine. (Moisan, 2001; Messerer, 2005; Roth, 2010;
Rossi, 2009; Shintani, 2007; Morfill, 2009) Non-thermal gas plasmas have
typically been used to alter the surface chemistry of plastics and metals. For
example, the surface characteristics of plastic microtiter plates for cell culture are
frequently altered using NtNP to enhance cellular adhesion. We hypothesized
that NtNP would not reduce bioadhesivity or MW of chitosan like conventional
sterilization methods since it is only a surface treatment and is not composed of
ionizing radiation. Additionally, we hypothesized that NtNP would increase the
nitrogen content, and thus the bioadhesion, of the Clo-Sur P.A.D. since NH3 gas
plasma exposure increases nitrogen content of CS films. (Ogino, 2008)

Materials and Methods
Materials
Unsterile and E-beam sterilized Clo-sur P.A.D.s were obtained from Scion
Cardio-Vascular, Inc. The P.A.D.s consist of lyophilized CS with each P.A.D.
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measuring 4 cm x 4 cm x 1 cm. The P.A.D.s are normally sterilized with a
standard dose of electron beam irradiation. Specifications for the Clo-Sur P.A.D.
are given in Table 3.

Table 3. Properties of chitosan-based Clo-Sur P.A.D.
Parameter
Chitin Source
Endotoxin Quantity
Loss on Drying
Ash
Viscosity
Molecular Weight
Turbidity
Degree of
Deacetylation
Insolubles
Residual Protein
Heavy Metals

Specification
Crab Shell
28 EU/g
12%
2%
4,000 cP
500 kDa
150 NTU
80%
2%
500 μm
5 ppm

Morphologic Characterization
The Clo-Sur P.A.D. was imaged with a Phenom G1 (Model 800-03103-02)
(FEI Co., Netherlands) scanning electron microscope (SEM). Before imaging, a
small sample of the P.A.D. was mounted on the support. The sample was then
sputtered with an approximately 6 nm layer of gold/palladium (Au/Pd) using a
Quorum Technologies SC7620 Mini Sputter Coater (Laughton, East Sussex,
UK), which deposits 10 nm coating/45 sec.
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Sterilization and Surface Modification with NtNP
Unsterile P.A.D.s were treated with NtNP using the IoN40 plasma system
(PVA-TePla America, Corona, CA) using medical-grade nitrogen gas, ammonia
gas, nitrous oxide gas, or compressed air. Power was 500 Watts, pressure was
maintained at 300 mTorr, and gas flow rate was 0.5 L/min. The sterilization dose
for each gas was determined first by treating paper spore strips containing 2 x
106 B. subtilis and G. stearothermophilis spores (Steris Corp., Mentor, OH) and
subsequently culturing spore extracts in tryptic soy agar plates for 72 hours
following USP chapter 55 guidelines. Minimum sterilization doses, defined as a
6-log reduction in CFUs, for each gas were identified and an overkill dose,
defined as 2x the minimum sterilization dose, were used for sterilizing the CS
PADs.
P.A.D.s were placed directly on the metal tray of the IoN40 for sterilization
and aseptically flipped every 5 minutes to ensure even plasma exposure. At the
end of the sterilization treatment, P.A.D.s were aseptically transferred to a sterile
vial for transport and storage until use. After initial tests showed increased
brittleness of the P.A.D.s after plasma treatment due to drying, sterile gauze
pads soaked with 5 mL of sterile water were added to the vials containing the
plasma-treated P.A.D.s to increase malleability.

Tissue Adhesion Studies
Bioadhesion studies were performed using pig bladders and a universal
materials testing machine (Electropuls E10000, Instron Inc., Norwood, MA, USA).
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Pig bladders were obtained (Farmer John, Los Angeles, CA, USA), drained of
urine, rinsed with cold 1X phosphate buffered saline, kept on ice, and splayed
open with a sterile scalpel immediately prior to use. Each pig bladder (n=3) was
cut into pieces such that enough pieces were available for testing one of each
type of P.A.D. Cut bladder pieces were placed on the base of the testing
machine and a stainless steel sheet with a 3.5 cm circular cutout was placed on
top of the bladder and fixed to the base with tape (Figure 19 A & B). The
stainless steel plate with a circular opening ensured consistent surface area
contact of tissue with P.A.D. samples. Clo-sur P.A.D.s were cut into 2 cm x 2 cm
squares and attached to the upper moveable arm of the testing machine using
double-sided tape (Figure 19 C). The P.A.D.s were brought into contact with the
tissue and compressed with 30 N of force for 30 seconds. After 30 seconds, the
P.A.D.s were removed from the tissue surface at a rate of 1 mm/s and the peak
force achieved when removing the P.A.D.s was recorded. 3 PADs were tested
from each group. Care was taken to ensure the tape fully immobilized the P.A.D.
and tissue during the compressing and peeling phases of the experiment.
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Figure 19. Instrument setup for testing of CS bioadhesivity. Porcine bladder tissue
was placed on stage of Electropuls E10000 under a stainless steel plate with a
circular cutout to expose a standard surface area of tissue (A & B). The stainless
steel plate was fixed to the stage with tape to prevent tissue movement. CS P.A.D.
was fixed with double-sided tape to a plate attached to the moveable arm(C).

Surface Atomic Concentration Analysis
X-ray photoelectron spectroscopy (XPS) characterization was carried out
using a Kratos AXIS ULTRADLD XPS system equipped with an Al Kα
monochromated X-ray source and a 165-mm mean radius electron energy
hemispherical analyzer. Vacuum pressure was kept below 3 x 10 -9 torr during
acquisition. Other data acquisition parameters are listed in Table 4.

Table 4. Experimental parameters for XPS measurements.
Element
Survey
N 1s
O 1s
C 1s

Start
1200
eV
410 eV
540 eV
300 eV

End

Step

Dwell

Sweep

P.E.

Sensitivity
Factor

-5 eV

1.0 eV

100 ms

1

80

Al. mono.

390 eV
520 eV
275 eV

0.1 eV
0.1 eV
0.1 eV

200 ms
200 ms
200 ms

10
5
5, 10

20
20
20

0.477
0.780
0.278
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Hemostasis Procedure
The hemostatic procedure used for this study was based on a previous
study assessing the hemostatic efficacy of Microporous Polysaccharide
Hemospheres® in rats. (Ersoy, 2007) After receiving approval for the study from
the Loma Linda University Institutional Animal Care and Use Committee, 30 2month old Sprague-Dawley rats (16 female, 14 male) were obtained (Charles
River, Inc., Charleston, SC, USA). All procedures for the handling and care of the
animals were carried out in accordance with the 1996 National Research
Council’s “Guide for the Care and Use of Laboratory Animals.” Rats were housed
2 per cage with food and water ad libitum. Immediately prior to the procedure,
rats were weighed, anesthetized with 3% isoflurane, and maintained with 2%
isoflurane. Once anesthetized, the rats were placed in a supine position, the hind
paws were immobilized such that the legs were maximally stretched
inferolaterally, and the groin region shaved.
A rostral to caudal incision in the epidermis and dermis was made with a
surgical scalpel blade No. 10 at the mid-clavicular line. The underlying fascia and
fat pad were removed using scissors and blunt dissection. The left femoral artery
was separated from the vein by removing the vasa vasorum using microsurgical
instruments under an operating microscope. A 25 G needle was inserted into the
left femoral artery approximately 2 mm distal to the deep femoral artery (Figure
20, middle panel). The 2 cm x 2 cm Clo-sur P.A.D. or cotton gauze was then
centered over the needle, and the needle removed. Once bleeding was
confirmed, a 200 g brass weight was placed on the P.A.D. and timing began. The
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weight was held in place manually ensuring no additional weight was applied.
The weight was removed every 30 seconds for a period of 15 seconds to
observe the wound for bleeding. Excess blood was removed using gauze to
enable visualization of the wound site, if necessary. The brass weight was placed
back on the P.A.D. after each 15-second observation period until hemostasis
was achieved (Figure 20, right panel). Time to hemostasis was recorded, as was
the severity of bleeding after each 30-second compression period. If hemostasis
was not achieved after 180 seconds, the artery was ligated using sutures to
prevent exsanguination.

Figure 20. Experimental procedure for rat hemostasis studies. The left panel
shows microsurgical scissors around the femoral vessels immediately prior to
transection with the P.A.D. centered over the wound site for application after
transection. The middle panel shows a needle within the femoral artery
immediately prior to removal. The right panel shows the Clo-Sur P.A.D. in the
wound site after a femoral artery puncture. Note that hemostasis has been
achieved with very little bleeding.
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After obtaining hemostasis on the left side, the right femoral vessels were
dissected as described above for the left side. Once both the femoral artery and
vein were isolated from the femoral nerve approximately 2 mm distal to the deep
femoral artery, microsurgical scissors were placed around the vessels and the
Clo-sur P.A.D. or cotton gauze was centered over the scissors (Figure 20, left
panel). The femoral vessels were then fully transected. Once bleeding was
visually confirmed, the 200 g weight was placed on the P.A.D. or gauze as
described above. In cases where hemostasis was not achieved after 180
seconds, the vessels were ligated with sutures or clips.
Arterial puncture and artery/vein transection were both performed in order
to model different wound types. Trauma wounds are highly complex with many
different types of vascular injury, many of which behave differently. For example,
vasoconstriction and vessel retraction can have a significant impact on bleeding
after transection, whereas puncture wounds exhibit this phenomenon to a lesser
degree, if at all.
After achieving hemostasis on both sides, the P.A.D.s were carefully
removed to assess clot stability first on the arterial puncture side followed by the
transection side. Assessing clot stability is important since re-bleeding is
frequently an issue during pre-hospital transport. Animals were then euthanized
by pentobarbital injection into the left ventricle.
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Hemostasis Scoring
A hemostasis scoring system was devised to characterize the extent of
hemorrhage at each 30-second time point. The four point scoring system was as
follows: (4) severe, easily observable bleeding; (3) mild, easily observable
bleeding; (2) minimal, difficult to observe bleeding; and (1) no observable
bleeding (i.e. hemostasis).

Statistical Analyses
Data were analyzed via one-way ANOVA and Tukey’s Post-hoc test with p
< 0.05 considered significant.

Results
PAD Morphology
SEM imaging of the P.A.D., shown in Figure 21, revealed a highly porous,
honeycomb-like structure. This porosity gives the P.A.D. a very large surface to
volume ratio, theoretically enhancing its hemostatic potential by maximizing
intercalation and entrapment of blood cells.
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Figure 21. SEM images of chitosan PAD. Morphologic analysis shows the PAD
has a porous, honeycomb-like structure. The images show the PAD at 78X
magnification (A), 500X magnification (B), and 1000X magnification (C).

Plasma Dosing
Three of the four nitrogen-based plasmas achieved sterility doses (i.e. 6
log reduction in bacterial spores) within 15 minutes of treatment. Figure 22 shows
the kill curves for each plasma type over 15 minutes. Notably, ammonia plasma
only reached a 5-log reduction even after 30 minutes, which means it failed to
achieve a sterility dose. Due to the inefficiency of ammonia plasma, we elected
not to test the bioadhesivity or hemostatic efficacy of ammonia plasma sterilized
P.A.D.s. For the hemostasis studies, P.A.D.s were treated with nitrogen gas
plasma for 30 minutes and air or nitrous oxide gas plasma for 20 minutes, since
these doses constituted overkill doses.
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Figure 22. Effect of different low-pressure plasmas on B. subtilis and G.
stearothermophilis spores over time. Each data point represents the average of 3
spore strips. Sterility dose is defined as 6 log reduction in spores.

Bioadhesivity
Bioadhesion results are shown in Figure 23. Although the bioadhesion
studies failed to demonstrate statistically significant results due to high intragroup variability, the 30-minute N2 gas plasma treated P.A.D.s showed a trend
toward higher bioadhesivity than all other samples tested. Additionally, air and
nitrous oxide gas plasma treatment for 20 minutes trended toward lower
bioadhesivity than all other treatments.
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Figure 23. Effect of different low-pressure plasmas on bioadhesivity of chitosan.
Data represent mean ± standard error of the mean (n=3 each group). None of the
results reached statistical significance.

Surface Atomic Concentrations
Table 5 shows that contrary to our hypothesis, air and nitrous oxide
plasma treatment for 20 minutes increased nitrogen content in the P.A.D.s by 4%
and 9% respectively, whereas N2 plasma treatment for 30 minutes only increased
nitrogen content by 2%.
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Table 5. Elemental composition of chitosan after different plasma sterilization
treatments.
Sample
No plasma
20 mins N2O
Plasma
20 mins Air
Plasma
30 mins N2 Plasma

% Oxygen
32
36

% Carbon
57
43

% Nitrogen
4
13

33

48

8

25

59

6

Hemostatic Efficacy
Time to Hemostasis
As shown in Figure 24, rats in each experimental group weighed 286-324
g on average, with no statistical difference between groups. Figure 25 shows that
time to hemostasis (TTH) after femoral artery puncture was significantly lower
(p<0.001) in the Clo-sur P.A.D. groups compared to gauze controls. This result is
further strengthened by the fact that bleeding was consistently greater in the
male rats compared to the females and the 3 gauze treated rats were all females
and hemostasis was still not achieved in even one of them within 180 seconds.
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Figure 24. Average weights of rats in each of the experimental groups. Data
presented as mean ± standard error of the mean. The mean values of the groups
were not statistically significantly different. Group numbers were as follows: EB
and Gauze (n=3); No plasma, N2O, EBN2, and Air (n=4); and N2 (n=5).
AIR – air plasma sterilization group; EB – electron beam sterilization group; N2O
– nitrous oxide plasma sterilization group; EBN2 – electron beam + N2 plasma
sterilization group.
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Figure 25. Time to hemostasis after puncture of femoral artery. Data represent
mean ± standard error of the mean. Group numbers were as follows: EB and
Gauze (n=3); No plasma, N2O, EBN2, and Air (n=4); and N2 (n=5). CS compared
to gauze was statistically significant for all CS samples (p <0.001).
AIR – air plasma sterilization group; EB – electron beam sterilization group; N2O
– nitrous oxide plasma sterilization group; EBN2 – electron beam + N2 plasma
sterilization group.

Although there was no statistically significant difference between the
P.A.D. groups, electron beam sterilized P.A.D.s trended toward a longer TTH
than unsterilized, native P.A.D.s. Interestingly, this trend was reversed when ebeam sterilized P.A.D.s were treated with N2 gas plasma for 30 minutes.(Fig. 25)
TTH results after femoral transection are shown in Figure 26. TTH was
significantly reduced (p<0.001) compared to gauze control for the femoral vessel
transection challenge with the N2 plasma treated P.A.D.s trending toward the
lowest TTH. Once again, there was no statistically significant difference in TTH
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between the P.A.D. groups. Treating E-beam sterilized P.A.D.s with 30 minutes
of N2 gas plasma again resulted in a lower mean TTH.

Figure 26. Time to hemostasis after transection of femoral artery and vein. Data
represent mean ± standard error of the mean. Group numbers were as follows: EB
and Gauze (n=3); No plasma, N2O, EBN2, and Air (n=4); and N2 (n=5). CS
compared to gauze was statistically significant for all CS samples (p <0.001).
AIR – air plasma sterilization group; EB – electron beam sterilization group; N2O
– nitrous oxide plasma sterilization group; EBN2 – electron beam + N2 plasma
sterilization group.

Hemostasis Score
Hemostasis scores shown over the course of the experiment are shown in
Figures 27 and 28. Both N2 plasma and E-beam sterilized P.A.D.s trended
toward worse hemostasis scores at 30 seconds in the arterial puncture model
compared to the other P.A.D. groups. E-beam sterilized P.A.D.s retained this
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trend for the transection model, but N2 sterilized P.A.D.s reversed this trend and,
in fact, demonstrated the lowest hemostasis score at 30 seconds. It is evident
that hemostasis scores for the e-beam sterilized P.A.D.s returned to levels
achieved by unsterilized P.A.D.s. when also treated with 30 mins of N2 plasma.

Figure 27. Hemostasis scores after puncture of femoral artery. Data at each time
point represent mean values. Group numbers were as follows: EB and Gauze
(n=3); No plasma, N2O, EBN2, and Air (n=4); and N2 (n=5).
AIR – air plasma sterilization group; EB – electron beam sterilization group; N2O
– nitrous oxide plasma sterilization group; EBN2 – electron beam + N2 plasma
sterilization group.
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Figure 28. Hemostasis scores after transection of femoral artery and vein. Data at
each time point represent mean values. Group numbers were as follows: EB and
Gauze (n=3); No plasma, N2O, EBN2, and Air (n=4); and N2 (n=5).
AIR – air plasma sterilization group; EB – electron beam sterilization group; N2O
– nitrous oxide plasma sterilization group; EBN2 – electron beam + N2 plasma
sterilization group.

Clot Stability
There was little, and in many cases, no re-bleeding when P.A.D.s were
removed from wound sites after hemostasis had been achieved. Additional
manual manipulation of the clot site rarely resulted in re-bleeding indicating
robust clotting had occurred.

Discussion
Our results provide strong evidence that the Clo-sur P.A.D., a 100% CS
hemostatic agent, is a superior hemostatic agent compared to gauze for arterial
and combined arterial/venous hemorrhage, which is contrary to findings reported
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by Fischer et al in 2004. That group reported that Clo-sur P.A.D. was worse than
cotton gauze in controlling hemorrhage in a porcine spleen-bleeding model. A
major limitation in comparing these two studies, of course, is the hemorrhages
produced by rat femoral vessels are certainly different in nature than
hemorrhages from pig spleens. However, this limitation does not weaken the
conclusion that the Clo-Sur P.A.D. is an effective hemostatic agent.
The currently used sterilization technique for Clo-Sur P.A.D.s, e-beam
irradiation, lengthens TTH in both arterial and combined arterial/venous
hemorrhage, though not statistically significantly. N2 plasma sterilized P.A.D.s
trended toward a lower TTH compared to e-beam sterilized P.A.D.s, but this
result also failed to reach statistical significance and was not entirely consistent
between the arterial and arterial/venous hemorrhages. The most consistent result
we obtained was with P.A.D.s treated with both e-beam and 30 minutes of N2
plasma. This combination consistently produced the lowest TTH and hemostasis
scores that were at least equivalent to native, non-sterilized PADs. Thus,
although plasma does not enhance the hemostatic efficacy of the native,
unsterilized CS P.A.D. as we initially hypothesized, it does return the hemostatic
efficacy of the P.A.D.s to baseline after e-beam treatment. This suggests that a
combined e-beam+plasma sterilization protocol might be optimal.
It is presently unclear why combined e-beam+plasma treatment generates
the best hemostatic results. We postulate that e-beam treatment initially alters
the CS functional groups, which produces a minor reduction in hemostatic
efficacy, but N2 plasma treatment then alters the functional groups again such
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that the initial hemostatic efficacy is reestablished. Effects due to heating might
play a role in the alterations induced by both e-beam and plasma. (Lim, 1999)
Future studies will seek to better characterize the changes in CS functional
groups that occur after e-beam treatment, N2 plasma treatment, and the
combination of both.
The XPS data represent initial evidence showing that functional group
alterations occur after plasma treatment. However, the changes induced by air,
nitrous oxide, and nitrogen plasmas deviated from the predicted outcomes.
Specifically, it is surprising that air and nitrous oxide plasmas demonstrated
greater increases in nitrogen content than nitrogen plasma. Surface alterations to
polymers induced by plasmas remains a poorly understood phenomenon.
(Cornelius, 2007; Ogino, 2008; Messerer, 2005)
The bioadhesion data produced in the present study suggest that overall
nitrogen content is not the driving factor in determining CS bioadhesion, but
rather the type of nitrogen functional groups present. For example, the degree of
acetylation dictates the charge density of CS and thus the electrostatic
interactions between CS and tissues. Thus, if plasma sterilization induces
changes in the degree of deacetylation, perhaps through heating and resultant
caramelization of the polymer, this may alter the bioadhesivity, and therefore the
hemostatic properties, of CS. Follow-up studies using FTIR and/or mass
spectrometric techniques will aid in clarifying this issue.
In the course of conducting these hemostasis studies it was noted that
there was no difficulty in fitting the P.A.D.s to the wound site. The P.A.D.s are
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pliable and easy to manipulate. This is important since one of the seven key
attributes of the ideal hemostat for pre-hospital use is that it should simple to
apply. Notably, the CS P.A.D.s tested in the present study also meet the other 6
criteria for the ideal pre-hospital hemostatic dressing, including being able to stop
large-vessel arterial and venous bleeding within 2 minutes of application, ready
to use without special preparation, lightweight and durable, stable and functional
at room temperature for at least 2 years, posing no risk of injury to tissue or
transmission of bacteria or viruses, and inexpensive. (Pusateri, 2006)
Additionally, P.A.D.s produced robust clots that may aid in reducing re-bleeding
that may occur during pre-hospital transport.

Conclusion
We demonstrated superior hemostatic efficacy of a chitosanic hemostat
(Clo-Sur P.A.D.) compared to gauze in a rat model of severe arterial bleeding
and combined arterial/venous bleeding. Nitrogen gas plasma sterilization of
these P.A.D.s maintains the bioadhesive and hemostatic properties of the
unsterilized P.A.D.s. Finally, treating e-beam sterilized chitosan P.A.D.s. with 30
minutes of nitrogen gas plasma reverts the hemostatic efficacy to levels
equivalent to native, unsterilized PADs.
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Abstract
Background and Objectives: No ideal hemostatic agent exists for laparoscopic
partial nephrectomy despite the need for complete hemostasis and sealing of the
urinary collecting system in this procedure. Chitosan is an emerging hemostatic
agent, but standard sterilization techniques affect its functional and biological
properties. This study sought to characterize the hemostatic efficacy and safety
of an implanted chitosan hemostat sterilized with either electron beam irradiation
or non-thermal nitrogen plasma in a porcine model of laparoscopic partial
nephrectomy.

Methods: Laparoscopic partial nephrectomies were performed on 6 farm pigs
and hemostasis achieved using only a chitosan hemostatic agent (Clo-Sur
P.A.D.) that was e-beam (n=3) or plasma sterilized (n=3). Number of pads
needed, estimated blood loss, operative time, nephrectomy size, warm ischemia
time, and pig weight were measured. Animals were monitored for complications
for 14 weeks. Retrograde ureteropyelography was performed to assess urine
leakage. Post-mortem examination was followed by histologic analysis.

Results: Complete hemostasis and collection system sealing was achieved in
both groups, but fewer pads were required (p = 0.056) and estimated blood loss
was lower (p = 0.096) with plasma-sterilized pads. No complications were
observed over 14 weeks and gross examination showed the chitosan was
encapsulated in a fibrous capsule. Histologic analysis revealed normal renal
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parenchyma, mild giant cell and macrophage infiltration into the fibrous capsule,
and absence of infection or significant tissue reactivity.

Conclusion: Chitosan pads alone provided effective hemostasis in laparoscopic
partial nephrectomy and were safe to implant. Plasma sterilization enhanced
hemostatic efficacy whereas e-beam accelerated resorption of chitosan.

Keywords: chitosan, plasma sterilization, hemostasis, hemostatic agents, nonthermal nitrogen plasma, laparoscopic partial nephrectomy, LPN, electron beam,
e-beam

Abbreviations: CS – chitosan; NtNP – non-thermal nitrogen plasma; LPN –
laparoscopic partial nephrectomy; LpP – low-pressure plasma; DD – degree of
deacetylation;
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Introduction
Partial nephrectomy has become the reference standard treatment for
small, clinical T1 tumors (<7 cm) in patients who are candidates for nephronsparing surgery (NSS) since equivalent oncologic and superior functional
outcomes have been demonstrated with partial nephrectomy compared to radical
nephrectomy. (Gill, 2010; Lee, 2000; Fergany, 2000; Lau, 2000) Laparoscopic
partial nephrectomy (LPN) is becoming the preferred approach to partial
nephrectomy due to comparable outcomes with LPN compared to open partial
nephrectomy (OPN). (Lane, 2007; Dominguez-Escrig, 2011) However, LPN is a
technically challenging procedure and has shown higher rates of bleeding and
urine leak complications. (Dominguez-Escrig, 2011; Aron, 2007; Gill, 2007)
Current methods used in combination or alone for achieving hemostasis and
sealing of the collecting system in LPN include electrocautery, harmonic scalpel,
suturing, and hemostatic agents. Amongst hemostatic agents, Surgicel (Ethicon,
Inc.) is the most commonly used, but there is no ideal hemostatic agent for LPN
at present. (Breda, 2007) Thus, new hemostatic agents to improve hemostatic
control and tissue sealing for LPN are needed.
In the present feasibility study, a chitosan (CS) hemostatic agent (Clo-Sur
P.A.D.™, Scion Biomedical, Inc., Miami, FL) was evaluated in a hypertensive
porcine survival model of LPN. CS is known as a highly effective hemostatic
agent, but has yet to be used as an implantable hemostat due to concerns
regarding pyrogen contamination and negative alterations to the material caused
by conventional sterilization methods including dry/wet heat, irradiation, and
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chemical sterilants. (Whang, 2005; Ulański, 1992; Dutkiewicz, 1989; Franca,
2013; Lim, 1998; Lim, 1999; Marreco, 2004; Rao, 1995) Thus, this study sought
to characterize the hemostatic efficacy of a lyophilized CS hemostatic pad in LPN
when sterilized by a conventional method – electron beam irradiation – or a novel
method of non-thermal nitrogen plasma (NtNP).
Plasma is considered the fourth state of matter, after solid, liquid, and gas,
and has emergent properties that gases do not like quasi-neutrality, collective
behavior, and controlled motion by electromagnetism. (Cornelius, 2007) Plasma
is used widely in a number of industries, but has only just begun being used in
medicine as a dry decontamination technique. (Kong, 2009) Plasmas contain
neutrals, ionized species, and excited atoms and molecules. The mechanism(s)
by which NtNP kills microbes, and inactivates spores, viruses, and pyrogens is
debated, but the leading hypothesis is that UV, reactive chemical species, and
physical etching all play a role. (Moisan, 2001)

Materials and Methods
Lyophilized, foam-like CS pads that are currently manufactured for topical
control of bleeding and infection control were obtained (Clo-Sur P.A.D. ™). Both
e-beam sterilized and unsterilized pads were obtained. The unsterilized CS pads
were sterilized with 30 minutes of non-thermal nitrogen plasma (NtNP) using the
IoN 40 plasma system (PVA-TePla America, Inc., Corona, CA, USA). Sterility
was confirmed by placing spore strips with 5.5 x 106 B. atrophaeus and G.
stearothermophilis spores (Steris Corporation, Mentor, OH, USA) in the IoN 40
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with the CS pads and subsequently culturing the spores with tryptic soy agar for
48-72 hours at 37°C and 58°C.
Six female farm pigs (S&S Farms, Santee, CA) with an average weight of
28.3 kg (range of 24-32 kg) were included in the study after obtaining approval
for the study from the Loma Linda University Institutional Animal Care and Use
Committee. All procedures for handling and care of the animals were carried out
in accordance with the 1996 National Research Council’s “Guide for the Care
and Use of Laboratory Animals.” Animals were split into two treatment groups,
where electron beam sterilized (ES) pads were used to control hemostasis in one
group and non-thermal nitrogen gas plasma sterilized (PS) pads were used in the
other.
After acclimating for a minimum of 4 days, each animal was sedated with
intramuscular telazole, intubated, and placed in the right lateral decubitus
position. The animal was then sterilely prepped and draped in the typical fashion.
Sedation was maintained with isoflurane or sevoflurane throughout the remainder
of the case. IV antibiotics were then administered. Blood was drawn for
preoperative chemistry panels and complete blood counts. Blood pressure was
monitored with a cuff placed on the left arm. Heart rate and SpO2 were monitored
by a pulse oximeter placed on either the ear or tongue. A 14-gauge Veress
needle was then inserted percutaneously into the abdomen and
pneumoperitoneum was established superior to the umbilicus.
Pneumoperitoneum was maintained between 12-15 mmHg throughout each
case. A 12 mm port was then placed and used as the camera port. Three
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additional 12 mm ports were subsequently placed under direct visualization.
Following this, the bowel was mobilized medially with use of a hook electrode
and the left renal vein and artery were identified. The entire renal unit including
the renal artery and vein were then circumferentially dissected free of
attachments with the hook electrode.
With hemostasis confirmed, a bulldog clamp (Aesculap, Inc., Center
Valley, PA, USA) was placed over the left renal artery. The lower pole of the left
kidney was then removed with sharp dissection. The collecting system was
entered in one animal from each treatment group. CS pads were rolled, passed
down a 12 mm port, and applied to the freshly cut surface of the kidney. At least
2 pads (4 cm X 4 cm) were applied to the cut surface of each kidney before the
bulldog clamp was removed. Epinephrine (1 μg/mL) was administered to
artificially raise the blood pressure and heart rate. Manual pressure was applied
to the CS pads via use of the laparoscopic instruments. If there was continued
bleeding observed after removing the bulldog clamp, then additional pads were
passed through a port and applied to the site of bleeding until hemostasis was
achieved. After complete hemostasis was achieved, the wound was observed for
re-bleeding and blood was removed from the abdomen via suction. The kidney
specimen was removed using the Endo Catch specimen pouch (Covidien, Inc.,
Minneapolis, MN). In 4 of 6 animals (2 in each group), peritoneum was pulled
over the kidney and closed using non-absorbable hemo-clips. The CS pads were
left in place. The 12 mm port sites were then closed under direct visualization
with the use of a Carter-Thomason device. Subcutaneous tissue was then closed
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with 4-0 Monocryl subcuticular sutures followed by Dermabond. The animal was
awakened and extubated.
The primary outcome measures were time to hemostasis, estimated blood
loss (EBL), number of pads required to achieve hemostasis, pre- versus
postoperative blood counts/chemistries, complications (e.g. urinoma, re-bleeding,
pyrogenic reaction, etc.) up to postoperative day 98, and histologic abnormalities.
Additional outcome measures included operative time and warm ischemia time
(WIT). Ultrasounds and blood counts/chemistries were performed immediately
postoperatively and at postoperative day 6. Retrograde pyelography was
performed immediately prior to euthanasia on day 98 by first inducing anesthesia
as described above. A polyurethane ureteral catheter (C.R. Bard, Inc, Covington,
GA, USA) was inserted using a standard cystoscope. Catheter placement was
confirmed via guide wire and fluoroscopy. Iohexol (Omnipaque 300, GE
Healthcare, Inc., Little Chalfont, Buckinghamshire, UK) was diluted 1:2 with
normal saline and injected via the cystoscope into the ureter and urinary pelvis of
each kidney. Integrity of the ureter, renal pelvis, and calices was determined by
fluoroscopy after injection of Iohexol.
After pyelograms were obtained, animals were sacrificed by lethal IV
injection of sodium pentobarbital. The LPN site and implanted CS were then
carefully examined grossly before harvesting the kidneys. Both kidneys were
fixed in 10% neutral buffered formalin before histologic analysis. For histology,
kidney samples were processed in a series of ethanol (70%-100%) washes
followed by xylenes and paraffin. Samples were then embedded in paraffin and
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sectioned at 7 μm. Sections were mounted on lysine-coated microscope slides
and heat-set overnight.
For hematoxylin and eosin (H&E) staining, samples were cleared with 2
washes of xylenes at 5 minutes each, followed by 5 minute washes with 100%,
95%, and 70% ethanol. Slides were subsequently washed for 5 minutes with
deionized water and then stained with hematoxylin Gill’s No. 1 (Sigma Aldrich,
St. Louis, MO, USA) for 3 minutes, washed with tap water for 5 minutes, dipped
8-12x in acid ethanol (1 mL HCl + 400 mL 70% ethanol), rinsed with tap water for
2 minutes, and rinsed with deionized water for 2 minutes. Samples were then
stained with eosin Y containing phelon (Sigma Aldrich) for 30 seconds, rinsed
with 95% ethanol for 15 minutes, 100% ethanol for 15 minutes, and xylenes for
45 minutes. The slides were cover slipped using Permount (Thermo Fisher
Scientific, Inc., Waltham, MA) and imaged with a standard light microscope. Two
board-certified pathologists – who were blinded to the identity of the specimens –
analyzed each of the stained sections.
Data are presented as mean ± standard error of the mean (SEM). Data
were analyzed using Student’s t-test with p <0.05 considered statistically
significant.

Results
Complete hemostasis was achieved in all 6 cases using only CS pads.
The pads, which are foam-like, were rolled, successfully passed through a 12
mm port, unfurled intraabdominally, and applied to the resected renal surface
(Figure 29). However, some difficulty was encountered initially with the PS pads
135

due to brittleness. This problem was solved in subsequent operations by raising
the relative humidity in the packaging of the PS pads after NtNP treatment with
water-soaked sterile gauze.

Figure 29. Deployment of the CS pad to the cut surface of the kidney under warm
ischemia. The Clo-Sur P.A.D. was furled and passed through the 12 mm port (left)
before being unfurled and applied to the cut surface of the kidney (right).

Complete hemostasis was achieved in all 6 animals, but fewer PS pads
were required to achieve complete hemostasis than ES pads (p = 0.0564), as
shown in Table 6. EBL was less in the PS pad treated group than the ES group
(Table 6), but the difference was short of statistical significance (p = 0.096).
Notably, 2 of the PS pad-treated animals had EBL < 20 cc and non-humidified
PS pads were used in the one PS pad-treated animal that had increased EBL
(110 cc). Table 1 also presents the nephrectomy specimen weights, WIT, and
mean operative times, respectively, which were not significantly different
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between groups. Blood chemistry values, which were also not significantly
different between groups and preoperatively to postoperatively, are presented in
Table 7. White blood cell counts were significantly lower postoperatively in the
PS pad treated group than the ES pad treated group.

Table 6. Surgical data for porcine laparoscopic partial nephrectomy with chitosan
hemostatic agent.
ES Pads
(n=3) (mean ± SEM)
3.67 ± 0.33
201.67 ± 65.09
11.14 ± 1.54

PS Pads
(n=3)(mean ± SEM)
2.5 ± 0.29
43.33 ± 33.33
8.27 ± 0.81

p-value

Number of Pads
0.056
EBL (mL)
0.096
WIT (mins)
0.174
Nephrectomy
6.65 ± 2.37
7.56 ± 1.83
0.776
Weight (g)
Operative Time
2.49 ± 0.32
2.39 ± 0.15
0.799
(hours)
EBL – estimated blood loss; WIT – warm ischemia time; SEM – standard error of
the mean
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Table 7. Blood Chemistry and Cell Counts Between Groups and Pre- Versus
Postoperatively.
ES Pads
(n=3)

PS Pads
(n=3)

p-value

RBC Pre

5.52±0.23

6.44±0.27

>0.05

RBC Post

5.60±0.43

6.15±0.63

>0.05

Hg Pre

8.0±0.44

9.0±0.44

>0.05

Hg Post

8.23±0.48

8.23±0.49

>0.05

HCT Pre

23.18%±1.05%

25.22%±1.16%

>0.05

HCT Post

23.67%±1.47%

23.66%±1.08%

>0.05

WBC Pre

14.33±1.72

13.23±1.47

>0.05

WBC Post

17.85±1.39*

9.13±0.73*

<0.05

CRE Pre

1.03±0.07

1.0±0.1

>0.05

CRE Post

0.80±0.0

0.93±0.12

>0.05

ALB Pre

3.80±0.44

3.73±0.13

>0.05

ALB Post

3.70±0.153

3.77±0.30

>0.05

BUN Pre

5.0±1.0

4.33±1.20

>0.05

BUN Post
5.0±1.0
4.33±1.20
>0.05
RBC – red blood cell count; pre – preoperative; post – postoperative; Hg –
hemoglobin; HCT – hematocrit; WBC – white blood cell count; CRE – creatinine;
ALB – albumin; BUN – blood urea nitrogen *p<0.05

Postoperative ultrasound and paracentesis revealed urine in the abdomen
of the ES pad treated animal in which the collecting system was breached, but
blood chemistry values and behavior were normal throughout the post-operative
period. Fluid was not observed via ultrasound in the abdomen of any animals
treated with PS pads. All animals were negative for urine leaks at 14 weeks as
assessed by retrograde ureteropyelography (Figure 30). However, minor
hematuria was observed for 5 days postoperatively in the PS pad treated animal
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in which the collecting system was entered. There was no evidence of infection
or pyrogenic responses in any animals up to 14 weeks after CS implantation.

Figure 30. Retrograde ureteropyelography. Representative pyelograms performed
14 weeks post-LPN of the right (images A and C) and left (images B and D) ureters
and calyces from both ES pad (images A and B) and PS pad (images C and D)
treated animals are shown. Urinary leakage was not observed in any animals.
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Figure 31 shows representative examples from both treatment groups of
the CS pads in relationship to the left kidney intraoperatively (A and D), in situ at
sacrifice (B and E), and after removal from the body and longitudinal sectioning
(C and F). Gross examination at sacrifice suggested modest breakdown of the
pads in both treatment groups with pads appearing as yellow masses (Fig. 31 B
and E). The CS was a paste-like consistency at sacrifice and appeared to be
encapsulated within a capsule, which is part of the normal response to any
foreign material implanted in a living organism (Fig. 31 C and F). (Anderson,
2001)
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Figure 31. Intraoperative, post-mortem in situ, and ex vivo sectioned views of the
CS pads. Images A-C show representative views of the ES pads and D-F show
representative views of the PS pads from one animal each. Images A and D show
the effect of epinephrine administration on hemostasis where epinephrine was
given to the animal shown in A, but not to the animal in image D. Note the
appearance of the CS implant after 98 days in B, C, E, and F.

The kidney parenchyma appeared normal upon histologic examination in
all 6 animals (Fig. 32). Additionally, the tissue around the kidney showed a typical
foreign body reaction in all 6 animals. The capsule that we observed surrounding
the implanted CS macroscopically only had small amounts of collagen
suggesting the capsule is primarily composed of an immune cell connective
tissue matrix. There were large populations of giant cells present in this matrix
that were frequently approximated to CS deposits or showing evidence of CS
engulfment by presence of CS in the giant cell cytoplasm (Figure 33). In areas
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with large numbers of giant cells there was less CS, suggesting degradation of
CS by giant cells. Also present were lymphocytes with evidence of germinal
centers likely consisting of B cells with small numbers of T cells (Figure 34).
However, additional studies are needed to characterize the ratio of B cell to T
cells. Leukocytes were observed, but in small numbers.
Infiltration of giant cells (and thus macrophages), lymphocytes, and
leukocytes around implanted foreign materials is expected based on extensive
literature reports on implantable medical devices. (Anderson, 2001) Notably,
None of the animals showed evidence of infection, hematoma, urinoma,
excessive tissue reactivity, or other pathologic abnormalities.

Figure 32. Appearance of kidney parenchyma in contact with plasma-sterilized CS.
H&E section showing kidney parenchyma of pig treated with psCS. No
abnormalities of the kidney parenchyma were observed in any animals, including
areas with direct CS contact.
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Figure 33. CS engulfment by giant cells. Images are representative examples of
giant cells (marked by arrows) engulfing CS (stained pink) in H&E stained sections.
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Figure 34. Germinal centers and immune cell infiltration. Image represents
an example of germinal centers (blue circular nodules) and immune cell
infiltration (blue streaks) in the inflammatory cell connective tissue matrix.
CS (stained pink) appears to be in different stages of degradation.
Operative border is evident on ride side of image with kidney parenchyma
at far right.

Discussion
A 100% CS pad (Clo-Sur P.A.D.™), currently marketed as an antimicrobial barrier and hemostatic agent for arterial catheterization procedures,
was shown in this feasibility study to be an effective hemostatic agent in a
porcine model of LPN. This is the first study to our knowledge to demonstrate
that NtNP efficiently sterilizes and depyrogenates CS while improving its in vivo
hemostatic efficacy compared to a conventional radiation-based sterilization
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method. Due to the small sample size in this study, many of the primary
endpoints failed to reach statistical significance, but the safety profile of the
implanted CS was unequivocal.
A major complication of NtNP treatment identified in this study was
dehydration of the CS, which led to brittleness making it difficult to roll the pad for
placement down the laparoscopic ports. Simply increasing the relative humidity
within the packaging by co-packaging with water-soaked sterile gauze not only
reduced the brittleness, but actually enhanced the malleability of the pads from
where it was prior to NtNP treatment. Since higher relative humidity accelerates
and enhances hydrolytic depolymerization of CS within 6 months, alternative
methods for increasing the malleability of CS are recommended. (Viljoen, 2014)
During the course of the LPN operations, it was noted that the PS pads
demonstrated greater adhesion to the peritoneum and cut renal surface
compared to ES pads. This enhanced bioadhesivity made unfurling the PS pads
more difficult due to increased adherence to the peritoneum, but provided
superior hemostasis by increasing adherence to the wound site and
subsequently reducing the number of pads required to achieve hemostasis, EBL,
and WIT. In agreement with previous porcine LPN studies using a similar
lyophilized CS hemostatic agent produced by HemCon, Inc., the CS pads – from
both treatment groups – effectively sealed the urinary collecting system. (Xie,
2008; Xie, 2012) However, since postoperative hematuria was observed in the
PS pad treated animal in which the urinary collecting system was breached
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whereas uroadomen was observed in the ES pad treated animal with collecting
system breach, it appears that PS pads are a better sealant.
Regardless of sterilization technique, the CS pads provided excellent
hemostasis in this porcine model of LPN without additional hemostatic
maneuvers. Inducing hypertension in the pigs via IV epinephrine bolus after
applying the PADs led to active hemorrhaging through the CS pads in all 4
animals receiving epinephrine (2 each group), but blood loss remained low in
these cases, including 3 with EBL ≤ 110 mL. Although there was a correlation
between when the heart rate and blood pressure began decreasing and
achievement of hemostasis, it remains unclear whether hemostasis was simply
delayed by the epinephrine bolus or unable to be established until the blood
pressure returned to a certain threshold. Regardless, improving the physical form
of the CS, possibly to a fibrous form, may overcome the issue of bleeding
through the CS agent in higher-pressure situations. Adding substances to the CS
that enhance malleability may also enhance its hemostatic efficacy by improving
its ease of manipulation and application.
It is important to note that pigs clot faster than humans due to higher
levels of clotting factors V, VIII, IX, XI, and XII, which suggests that CS pads
might not be sufficient when used alone in human LPN procedures. (Roussi,
1996) However, the aforementioned porcine LPN studies found that CS achieved
hemostasis in porcine LPN procedures even after large doses of heparin were
given preoperatively. (Xie, 2008; Xie, 2012) These data suggest that CS may in
fact be effective as a lone hemostatic agent in humans as well. Alternatively,
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improving the application techniques may prevent hemorrhage under
hypertensive conditions.
It is unclear whether the marginal resorption of the pads observed after 14
weeks poses a potential problem. The HemCon CS hemostatic agent
demonstrated a similarly slow resorption at 6 months and 1 year after porcine
LPN and both the tissue reactivity and inflammatory response to the HemCon CS
was similar to the reaction induced by Surgicel/Tisseel. (Xie, 2012) The CS pads
used in the present study elicited tissue and inflammatory reactions similar to
those observed with HemCon CS and Surgicel/Tisseel. Additional studies will
focus on the significance of the germinal centers observed within the
inflammatory cell matrix and time-course of the inflammatory reaction that is
generated.
Although there was little tissue and immune reactivity to the CS in the
kidney parenchyma at the 98-day mark, this could change over time since foreign
bodies induce a chronic inflammatory environment. (Anderson, 2001) Thus, a
physical form of CS that is resorbed within weeks or months might be ideal. In
addition to alterations in physical form that may accelerate resorption, chemical
alterations may be important as well. For example, a previous study in rats found
that CS films with degree of deacetylation (DD) of 68.8% resorbed significantly
faster than CS films with DDs ≥ 73.3%. (Tomihata, 1997) An in vitro study
analyzing degradation of CS films by lysozyme recapitulated these findings by
showing >50% reduction in mass of CS films after 4 weeks with DDs of 30-70%,
but minimal degradation of CS films with DDs of >70%. (Freier, 2005) The CS
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used in the present study has a DD of approximately 80% suggesting the DD
may be responsible for the marginal resorption observed in the current study.
Notably, the HemCon CS has a similar DD. (Xie, 2008)
Although zero ischemia approaches to LPN and robotic partial
nephrectomy (RPN) are in development with promising results, hemostatic
agents will remain a critical tool in the performance of these operations.
(Lamoshi, 2015) For example, Gill and colleagues report using a Surgicel bolster
with their zero ischemia RPN. (Gill, 2011) Perhaps a CS bolster would provide
superior hemostatic control compared to the oxidized regenerated cellulose
bolsters currently used making a complicated procedure like zero ischemia LPN
and RPN procedures easier to perform and therefore achievable for more
surgeons.
Weaknesses of the present study include the small number of animals and
resultant small number of statistically significant findings. Use of a porcine model
is also a potential weakness since renal vessels in the pig are generally smaller
than human renal vessels and pigs have higher levels of clotting factors. These
issues were addressed to some degree through induction of hypertension via
epinephrine bolus. Since major collecting system breach was only performed in 2
animals, the ability of CS to seal the collecting system could be called into
question. However, when the kidney is cut transversely, there will be open
collecting tubules that must be sealed to prevent urinoma. Thus, it is unequivocal
that CS sufficiently seals the proximal parts of the collecting system. Since serum
CS antibody titers were unable to be assessed due to absence of a commercially
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available anti-CS antibody, the ability to determine whether chitosan results in a
significant systemic inflammatory response could not be assessed. Finally,
without a comparison to gold standard hemostatic agents, the true hemostatic
efficacy of CS for LPN cannot be adequately assessed. However, the data
provide sufficient evidence to support additional studies of plasma-sterilized CS
as a hemostatic agent for use in LPN procedures and provide proof-of-concept
data for the efficacy of plasma sterilization and depyrogenation of CS. Several
alterations to the CS may enhance its efficacy for LPN such as larger and or
thinner pad sizes, use as a bolster, or even a different physical or chemical form
entirely. Future studies will compare CS to currently used hemostats (e.g.
FloSeal, Surgicel, and GelFoam) and will explore other physical forms of CS.

Conclusion
A 100% CS pad used alone is an effective hemostatic agent for LPN
procedures and NtNP effectively sterilizes and depyrogenates CS while
preserving or enhancing its in vivo hemostatic properties. Implantation of the CS
pad, regardless of sterilization technique, did not produce complications and
elicited tissue reactivity characteristic of foreign body implants. Marginal
resorption of the CS pad was observed after 14 weeks with ES pads appearing
further resorbed than PS pads. Future studies to further develop CS – NtNPsterilized CS especially – for LPN are warranted.
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CHAPTER SIX
DISCUSSION
In an effort to overcome the major barrier preventing translation of
numerous promising clinical applications of CS, we hypothesized that NtNP
would effectively sterilize and depyrogenate CS while preserving its biological
properties.
To test our hypothesis, we first micronized CS via cryo-milling in order to
maximize the surface to volume ration and to enhance the solubility of the raw
CS flake we obtained from Scion Biomedical, Inc. (Chapter 2). We found that
cryo-jet milling was superior to cryo-ball milling in reducing the particle size of
CS. Although cryo-ball milling might be capable of generating similar mean and
D95 values with alternative parameters, we used cryo-jet milled CS powder for all
our future studies since it outperformed cryo-ball milling in our studies.
Additionally, concerns were raised regarding potential metal contamination in the
CS when micronized via cryo-ball milling since metal balls are used under very
physically strenuous conditions and may shed metal particles during the milling
procedure. Cryo-jet milling avoids this problem all together.
Since the biological properties of CS are dependent on its physicochemical properties, we next characterized the physico-chemical properties of
the CS flake and micronized CS powder. Cryo-jet milling produced a substantial
reduction in the viscosity, and thus the MW of CS. This was expected since the
raw CS flake is a very large MW and single chain breaks in the CS polymeric
chain would be expected to reduce the MW quite substantially. We were,
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however, surprised to find that DD was reduced by 9.6% after cryo-jet milling and
the chemical spectra of CS had a shift at 1100 cm-1. We hypothesize that these
changes occur due to chain breaks that lead to alterations in the functional
groups in CS and subsequently to chemical reactions. However, other
mechanisms, like heat-induced caramelization of the CS, are possible. Heating of
a cryogenically cooled CS might seem counterintuitive, but studies have shown
that very high temperatures are generated for very short times (< 10 -6 s) during
high-force collisions and micronization of materials, making this a plausible
explanation. (Rumpf, 1973; Weichert, 1976). The changes we observed in the
physico-chemical properties of CS did not alter the drug delivery efficacy of CS in
the mouse model of bladder cancer (Chapter 3). This is a very significant finding
since one of the primary goals of this project was to demonstrate preserved
biologic properties of CS after NtNP sterilization.
Our results not only demonstrated preservation of the biologic functionality
of cryomilled CS, but also of NtNP-sterilized CS. (Chapter 3) Notably, NtNP
sterilization further reduced the DD, viscosity, and MW of CS, likely through
mechanisms similar to those discussed above for cryo-milling, but preserved its
bioadhesive properties. The fact that the bioadhesive properties of CS were
preserved with NtNP sterilization suggests that the cationic charge of the CS was
unchanged. It follows that the drug delivery properties of CS are dependent on
the cationic charge and not so much on MW and DD. However, other studies
suggest that reductions in MW and DD would eventually affect the drug delivery
properties of CS once some unknown threshold is reached. (Roy, 2010)
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Regardless, the finding that CS’s biologic properties are retained despite
reductions in DD and MW is a very important observation since significant
fluctuations in the MW and DD of CS can occur based on the individual crabs
from which the chitin was extracted. (Kumirska, 2011) Thus, some fluctuations
might be acceptable so long as minimum thresholds, in terms of MW and DD, are
not crossed. Additional studies are needed to identify these thresholds.
Our studies on endotoxins were difficult to interpret. We found that
endotoxin standards are not reliable, which dramatically reduced our ability to
identify the optimal NtNP parameters for pyrogen inactivation. This conclusion is
supported by a report on endotoxin testing of pharmaceuticals and medical
devices by FDA and industry experts in endotoxin testing. (Bryans, 2004)
Moreover, CS samples demonstrate highly variable endotoxin concentrations
between samples. With the high between-sample variability in endotoxin
concentrations and < 1-log reductions in endotoxins we were observing, it was
impossible to determine with confidence the true magnitude of endotoxin
reduction we were accomplishing. However, our results showed that ApPsterilized CS consistently generated CS with endotoxins that were lower than
LpP-sterilized CS. (Chapter 2) We believe this is a result of lower gas
concentrations in the LpP system and reduced free radical generation in the LpP
system due to superior removal of air contaminants. Thus, our future studies will
focus on ApP systems.
For the purposes of this project, we decided not to further pursue
optimization of NtNP parameters to reduce pyrogens in CS. The primary reason
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was we found that neither the LpP nor the ApP systems we were using were
suited for treating the physical forms of CS we were testing. The powder was
especially difficult since it had to be packaged for plasma treatment. This
prevented direct exposure to the plasma and might have prevented venting of
volatilized contaminants, like the endotoxin lipopolysaccharide. It is believed that
one mechanism by which plasma inactivates pyrogens, and other biological
macromolecules, is through oxidation which leads to volatilization. (Von Keudell,
2010) However, if CS is packaged in a sterilization pouch where it is isolated
from the gas flowing through the chamber, this mechanism might be hampered.
Additionally, it is our opinion that movement of the particles during plasma
treatment is needed to ensure all surfaces of the 3-dimensional structure of the
CS particles are equally exposed to plasma. Thus, we have begun working with
plasma engineers at North Carolina State University to build custom plasma
instruments that will be specifically designed for treating CS powder and textiles.
In spite of our difficulty with reducing endotoxins > 1 log – we intended to
achieve ≥ 3-log reduction – we were able to generate a CS hydrogel with
endotoxin levels (0.02 EU/mL) that are below the regulatory threshold (0.5
EU/mL) for parenteral uses. With our mouse data demonstrating the preservation
of the drug delivery properties of CS in vivo after NtNP sterilization, we believe
we have a CS preparation that will be safe and effective for human use. Thus, we
are currently working with the NCI on organizing a Phase I clinical trial in human
bladder cancer patients.
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If human trials show a positive safety profile for CS+IL-12, a large number
of potential applications for CS would be enabled. For example, we have
identified 3 intravesical applications in which CS would act as a sole therapeutic
agent. First, based on the anti-microbial properties of CS, an intravesical injection
of CS might be an effective treatment for recurrent urinary tract infections. (Chan,
2013) Second, based on the anti-oxidative properties of CS, an intravesical
injection of CS before, during, and/or after pelvic irradiation might protect the
bladder from the development of radiation-induced cystitis. (Crew, 2001) Third,
based on the hemostatic properties of CS, an intravesical injection of CS might
be an effective treatment for hemorrhagic cystitis (HC). HC is a major unsolved
clinical problem with significant morbidity. (Manikandan, 2010) Beyond the
bladder, mouse studies suggest CS+IL-12 might be useful for a range of other
malignancies including breast, colorectal, ovarian, and pancreatic tumors. (Vo,
2014; Yang, 2013; Zaharoff, 2010; Hurteau, 2001; Lenzi, 2002) We believe
human trials testing CS+IL-12 for the treatment of these malignancies are
indicated and are now enabled by NtNP-sterilized CS. The tremendous preclinical literature on CS suggests it might be an effective delivery vehicle for a
range of drugs and biologicals.
Our mouse studies (Chapter 3) showed that CS+IL-12 might be an
effective vaccine for individuals at high risk of developing bladder tumors since
tumor establishment rates were significantly lower in mice treated with CS+IL-12
prior to tumor cell instillation than treatment-naïve mice. On the other hand,
widespread adoption of such a vaccine might be stymied by the high cost of
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producing recombinant human proteins for therapeutic use. On the other hand,
CS should be investigated more generally as a replacement for aluminum-based
vaccine adjuvants. Numerous studies have shown the superiority of CS
adjuvants over conventional adjuvants. (Li, 2015; Mori, 2012; Powell, 2015;
Villiers, 2009; Vo, 2014; Yang, 2013; Zaharoff, 2007) Additionally, CS may
enable non-invasive vaccines that are delivered via the nasal mucosa or even
orally. (Illum, 1994; Xia, 2015)
The other clinical application of CS we sought to advance toward clinical
testing in this set of studies was an implantable hemostatic agent. Our studies in
a rat femoral bleeding model (Chapter 4) reinforced the exceptional hemostatic
efficacy of CS. Though these studies failed to produce statistically significant
findings in terms of the impact of sterilization procedures on CS, they
unequivocally showed that CS is superior to standard gauze with pressure in
achieving hemostasis. There was also a trend that suggested hemostatic efficacy
of NtNP-sterilized CS is superior to e-beam sterilized CS. Unexpectedly, our
results suggest that a combination approach to sterilization, in which CS is
treated with both e-beam irradiation and NtNP, might be ideal for preserving the
full hemostatic potential of CS since this combination consistently induced
hemostasis at the same rate as unsterilized CS. Further studies are needed to
confirm the validity of these findings and the mechanism by which this
phenomenon occurs.
Our large animal hemostasis study (Chapter 5), based on porcine LPN,
strengthened the non-significant trend observed in the rat study (Chapter 4) that
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NtNP-treated CS has superior hemostatic properties compared to e-beam
sterilized CS. More importantly, the long-term nature of this study provides
preliminary evidence that NtNP-sterilized CS can be safely implanted without
causing an infection or pyrogenic response. These results are in agreement with
two previous porcine LPN studies that showed a similar CS hemostatic agent,
the HemCon Bandage, is effective in controlling bleeding during LPN, seals the
urinary collecting system, and does not cause significant adverse tissue
reactivity. (Xie, 2008; Xie, 2012) This pilot study provides sufficient evidence for
moving forward with developing an implantable NtNP-sterilized CS hemostatic
agent for LPN and a range of other surgical operations in which hemostasis is
technically challenging. However, our results also suggest that an improved
physical formulation of CS, perhaps a fabric or excelsior-type form, may enhance
the hemostatic efficacy and the rate of resorption after implantation. Since the CS
pads used in the present study only showed minimal resorption, it might be
necessary to use a CS with a lower DD or reduce the DD with a rinse after the
hemostatic agent has been applied to the surgical site since CS films with lower
DDs resorb significantly faster than CS films with higher DDs. (Tomihata, 1997)

Conclusions and Future Directions
Our primary goal currently is more clinical translation than basic science.
We intend to produce enough NtNP-sterilized CS of GMP quality to enable the
NCI to move forward with human trials to assess the safety and efficacy of
CS+IL-12 in treating non-muscle invasive bladder cancer. Scientifically, our
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future experiments will begin with characterizing the aforementioned custom-built
plasma instrument(s) in terms of depyrogenation capabilities and effects on
physico-chemical properties of CS. Our goal will be to achieve a minimum 3-5 log
reduction in endotoxins since similar results have been shown by other groups.
(Shintani, 2007; Park, 2007; Von Keudell, 2010) We also seek to reduce the
sterilization dose from 15 minutes to 5 minutes or less. One of our primary goals
will be to identify the key factors in achieving high depyrogenation rates with nonthermal plasmas. Finally, we plan to initiate additional animal studies assessing
the hemostatic efficacy of different physical forms of NtNP-sterilized CS in other
surgical operations, including those on the spleen, liver, and brain. For LPN
procedures, we plan to compare CS to other currently-used hemostatic agents
like FloSeal, GelFoam, and Surgicel in terms of hemostatic efficacy and tissue
reactivity after implantation.
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